Publications

Journals

Kiriakidis S; Andreakos E; Monaco C; Foxwell B; Feldmann M; Paleolog E. (Apr 2003). REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN RHEUMATOID ARTHRITIS BY THE TRANSCRIPTION FACTOR NF kappa B. RHEUMATOLOGY. 42:42-43.
Monaco C; Andreakos E; Kiriakidis S; Feldmann M; Paleolog E. (Apr 2002). REQUIREMENT FOR NF kappa B AND IKK-2 IN TISSUE FACTOR EXPRESSION BY CELLS RELEVANT TO THE PATHOGENESIS OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS. RHEUMATOLOGY. 41:32-32.
Kiriakidis S; Andreakos E; Monaco C; Foxwell B; Feldmann M; Paleolog E. (Apr 2002). VEGF EXPRESSION IN HUMAN MACROPHAGES IS NF kappa B-DEPENDENT: STUDIES USING ADENOVIRUSES EXPRESSING A KINASE DEFECTIVE FORM OF IKK2 or I kappa B alpha THE NATURAL NF kappa B INHIBITOR. RHEUMATOLOGY. 41:66-66.
Afuwape AO; Feldmann M; Paleolog EM. (Apr 2002). ADENOVIRAL DELIVERY OF SOLUBLE VEGF RECEPTOR (sFLT-1) ABROGATES DISEASE ACTIVITY IN MURINE COLLAGEN INDUCED ARTHRITIS. RHEUMATOLOGY. 41:10-10.
Andreakos E; Kiriakidis S; Monaco C; Smith C; Foxwell B; Paleolog E; Feldmann M. (Apr 2002). SELECTIVE USAGE OF IKK2 FOR NF-kappa B ACTIVATION AND PRO-INFLAMMATORY GENE EXPRESSION: STUDIES IN HUMAN PRIMARY CELLS AND RHEUMATOID SYNOVIAL MEMBRANE CELL CULTURES. RHEUMATOLOGY. 41:65-65.
Andersson AK; Sumariwalla PF; McCann FE; Amjadi P; Chang C; McNamee K; Tornehave D; Haase C; et alAgersø H; Stennicke VW; Ahern D; Ursø B; Trowsdale J; Feldmann M; Brennan FM. (Sep 2011). Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. Arthritis Rheum. 63:2617-2629. DOI.
McNamee KE; Alzabin S; Hughes JP; Anand P; Feldmann M; Williams RO; Inglis JJ. (Aug 2011). IL-17 induces hyperalgesia via TNF-dependent neutrophil infiltration. Pain. 152:1838-1845. DOI.
Krausgruber T; Blazek K; Smallie T; Alzabin S; Lockstone H; Sahgal N; Hussell T; Feldmann M; et alUdalova IA. (Mar 2011). IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 12:231-238. DOI.
Cole JE; Navin TJ; Cross AJ; Goddard ME; Alexopoulou L; Mitra AT; Davies AH; Flavell RA; et alFeldmann M; Monaco C. (8 Feb 2011). Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A. 108:2372-2377. DOI.
Glass GE; Chan JK; Freidin A; Feldmann M; Horwood NJ; Nanchahal J. (25 Jan 2011). TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci U S A. 108:1585-1590. DOI.
Terrando N; Monaco C; Ma D; Foxwell B; Feldmann M; Maze M. (2010). Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A. DOI.
Terrando N; Fidalgo AR; Vizcaychipi M; Cibelli M; Ma D; Monaco C; Feldmann M; Maze M. (2010). The impact of IL-1 modulation on the development of LPS-induced cognitive dysfunction. Crit Care. 14. DOI.
Turner JJ; Foxwell KM; Kanji R; Brenner C; Wood S; Foxwell BM; Feldmann M. (Dec 2010). Investigation of nuclear factor-κB inhibitors and interleukin-10 as regulators of inflammatory signalling in human adipocytes. Clin Exp Immunol. 162:487-493. DOI.
Smallie T; Ricchetti G; Horwood NJ; Feldmann M; Clark AR; Williams LM. (27 Sep 2010). IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med. 207:2081-2088. DOI.
Cibelli M; Fidalgo AR; Terrando N; Ma D; Monaco C; Feldmann M; Takata M; Lever I; et alNanchahal J; Fanselow M; Maze M. (2010). Role of Interleukin-1β in Postoperative Cognitive Dysfunction. Ann Neurol. 68:360-368. DOI.
Page TH; Turner JJ; Brown AC; Timms EM; Inglis JJ; Brennan FM; Foxwell BM; Ray KP; et alFeldmann M. (15 Sep 2010). Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol. 185:3694-3701. DOI.
Feldmann M; Maini RN. (15 Jul 2010). Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. J Immunol. 185:791-794. DOI.
McCann FE; Palfreeman AC; Andrews M; Perocheau DP; Inglis JJ; Schafer P; Feldmann M; Williams RO; et alBrennan FM. (2010). Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 12:R107. DOI.
Terrando N; Fidalgo AR; Vizcaychipi MP; Cibelli M; Ma D; Monaco C; Feldmann M; Maze M. (May 2010). The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Critical Care. Publisher weblink.
Malik NM; Jin P; Raatz Y; Sumariwalla PF; Kiriakidis S; Shepard M; Feldmann M; Paleolog EM. (Oct 2010). Regulation of the angiopoietin-Tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis. Rheumatology (Oxford). 49:1828-1839. DOI.
Drexler SK; Wales J; Andreakos E; Kong P; Davis A; Garlanda C; Mantovani A; Hussell T; et alFeldmann M; Foxwell BM. (Jun 2010). Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR. Scand J Immunol. 71:393-402. DOI.
Weng L; Williams RO; Vieira PL; Screaton G; Feldmann M; Dazzi F. (Aug 2010). The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. Ann Rheum Dis. 69:1519-1526. DOI.
Drexler SK; Kong P; Inglis J; Williams RO; Garlanda C; Mantovani A; Yazdi AS; Brennan F; et alFeldmann M; Foxwell BM. (Aug 2010). SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum. 62:2249-2261. DOI.
McNamee KE; Burleigh A; Gompels LL; Feldmann M; Allen SJ; Williams RO; Dawbarn D; Vincent TL; et alInglis JJ. (May 2010). Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 149:386-392. DOI.
Wegner N; Lundberg K; Kinloch A; Fisher B; Malmstrom V; Feldmann M; Venables PJ. (Jan 2010). Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. IMMUNOL REV. 233:34-54.
Feldmann M; Williams RO; Paleolog E. (Jan 2010). What have we learnt from targeted anti-TNF therapy?. ANN RHEUM DIS. 69:97-99. DOI.
Monaco C; Gregan SM; Navin TJ; Foxwell BMJ; Davies AH; Feldmann M. (15 Dec 2009). Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis. CIRCULATION. 120:2462-2469. DOI.
Hillyer P; Larche MJ; Bowman EP; McClanahan TK; Malefyt RD; Schewitz LP; Giddins G; Feldmann M; et alKastelein RA; Brennan FM. (Dec 2009). Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. RHEUMATOLOGY. 48:1581-1589. DOI.
Feldmann M. (Oct 2009). A view from a European medical academic who spends time in the US. J CLIN INVEST. 119:2861-2862. DOI.
Taylor PC; Feldmann M. (Oct 2009). Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. NAT REV RHEUMATOL. 5:578-582. DOI.
Gasparini C; Foxwell BMJ; Feldmann M. (Aug 2009). RelB/p50 regulates CCL19 production, but fails to promote human DC maturation. EUR J IMMUNOL. 39:2215-2223. DOI.
Feldmann M. (2009). Translating Molecular Insights in Autoimmunity into Effective Therapy. ANNU REV IMMUNOL. 27:1-27. DOI.
Brennan F; Feldmann M. (2009). In memoriam: Professor Brian Maurice John Foxwell, 1956 to 2008. Arthritis Res Ther. 11:104. DOI.
Sumariwalla PF; Palmer CD; Pickford LB; Feldmann M; Foxwell BMJ; Brennan FM. (Jan 2009). Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. RHEUMATOLOGY. 48:32-38. DOI.
Sacre SM; Lo A; Gregory B; Simmonds RE; Williams L; Feldmann M; Brennan FM; Foxwell BM. (1 Dec 2008). Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures. J IMMUNOL. 181:8002-8009.
Feldmann M. (Nov 2008). Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 118:3533-3536. DOI.
Sumariwalla PF; Jin P; Zhang J; Ni I; Crawford D; Shepard HM; Paleolog EM; Feldmann M. (Oct 2008). Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. Arthritis Rheum. 58:3071-3080. DOI.
Raichel L; Berger S; Hadad N; Kachko L; Karter M; Szaingurten-Solodkin I; Williams RO; Feldmann M; et alLevy R. (Oct 2008). Reduction of cPLA(2 alpha) overexpression: An efficient anti-inflammatory therapy for collagen-induced arthritis. EUR J IMMUNOL. 38:2905-2915. DOI.
Inglis JJ; McNamee KE; Chia SL; Essex D; Feldmann M; Williams RO; Hunt SP; Vincent T. (Oct 2008). Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. Arthritis Rheum. 58:3110-3119. DOI.
Feldmann M. (Aug 2008). Cytokine blockade: a major improvement in translational medical research. FUND CLIN PHARMACOL. 22:23-23.
Andersson AK; Feldmann M; Brennan FM. (Jul 2008). Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. SCAND J IMMUNOL. 68:103-111. DOI.
Feldmann M; Maini RN. (Jun 2008). Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. IMMUNOL REV. 223:7-19.
Williams LM; Lali F; Willetts K; Balague C; Godessart N; Brennan F; Feldmann M; Foxwell BM. (May 2008). Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol Immunol. 45:2446-2454. DOI.
Simelyte E; Criado G; Essex D; Uger RA; Feldmann M; Williams RO. (Apr 2008). CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum. 58:1038-1043. DOI.
Elliot MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katasikis P; Brennan FM; Bijl H; et alGhrayeb J; Woody JN. (Feb 2008). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 58:S92-S101. DOI.
Jin P; Zhang J; Sumariwalla PF; Ni I; Jorgensen B; Crawford D; Phillips S; Feldmann M; et alShepard HM; Paleolog EM. (2008). Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. ARTHRITIS RES THER. 10. DOI.
Brennan FM; Smith NMG; Owen S; Li C; Amjadi P; Green P; Andersson A; Palfreeman AC; et alHillyer P; Foey A; Beech JT; Feldmann M. (2008). Resting CD4(+) effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. ARTHRITIS RES THER. 10. DOI.
Inglis JJ; Notley CA; Essex D; Wilson AW; Feldmann M; Anand P; Williams R. (Dec 2007). Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 56:4015-4023. DOI.
Wales J; Andreakols E; Feldmann M; Foxwell B. (Dec 2007). Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination. BIOCHEM SOC T. 35:1501-1503. DOI.
Wales J; Foxwell B; Feldmann M. (Dec 2007). Targeting intracellular signaling: a novel approach to vaccination. EXPERT REV VACCINES. 6:971-980. DOI.
Sacre SM; Drexler SK; Andreakos E; Feldmann M; Brennan FM; Foxwell BMJ. (Nov 2007). Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. ANNALS OF THE RHEUMATIC DISEASES. 66:81-86. DOI.
Lundberg AM; Drexler SK; Monaco C; Williams LM; Sacre SM; Feldmann M; Foxwell BM. (1 Nov 2007). Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood. 110:3245-3252. DOI.
Inglis JJ; Criado G; Andrews M; Feldmann M; Williams RO; Selley ML. (Sep 2007). The anti-allergic drug, N-(3 ',4 '-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. RHEUMATOLOGY. 46:1428-1432. DOI.
Williams RO; Paleolog E; Feldmann M. (Aug 2007). Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol. 7:412-417. DOI.
Sheryanna A; Bhangal G; McDaid J; Smith J; Manning A; Foxwell BM; Feldmann M; Cook HT; et alPusey CD; Tam FW. (Apr 2007). Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol. 18:1167-1179. DOI.
Bondeson J; Lauder S; Wainwright S; Amos N; Evans A; Hughes C; Feldmann M; Caterson B. (Mar 2007). Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol. 34:523-533.
Sacre SM; Lundberg AM; Andreakos E; Taylor C; Feldmann M; Foxwell BM. (15 Feb 2007). Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NF-kappaB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling. J Immunol. 178:2148-2154.
Sacre SM; Andreakos E; Kiriakidis S; Amjadi P; Lundberg A; Giddins G; Feldmann M; Brennan F; et alFoxwell BM. (Feb 2007). The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol. 170:518-525. DOI.
Inglis JJ; Criado G; Medghalchi M; Andrews M; Sandison A; Feldmann M; Williams RO. (2007). Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. ARTHRITIS RES THER. 9. DOI.
Brent L; Cohen IR; Doherty PC; Feldmann M; Matzinger P; Holgate ST; Lachmann P; Mitchison NA; et alNossal G; Rose NR; Zinkernagel R; Ghost Lab. (Jan 2007). Crystal-ball gazing - the future of immunological research viewed from the cutting edge. CLIN EXP IMMUNOL. 147:1-10. DOI.
Edwards CJ; Feldman JL; Beech J; Shields KM; Stover JA; Trepicchio WL; Larsen G; Foxwell BM; et alBrennan FM; Feldmann M; Pittman DD. (Jan 2007). Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med. 13:40-58. DOI.
Maini RN; Feldmann M. (Jan 2007). The pitfalls in the development of biologic therapy. NAT CLIN PRACT RHEUM. 3:1-1. DOI.
Amos N; Lauder S; Evans A; Feldmann M; Bondeson J. (Oct 2006). Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor I kappa B alpha reveals that most, but not all, inflammatory and destructive mediators are NF kappa B dependent. RHEUMATOLOGY. 45:1201-1209. DOI.
Andreakos E; Williams RO; Wales J; Foxwell BM; Feldmann M. (26 Sep 2006). Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci U S A. 103:14459-14464. DOI.
Feldmann M; Pusey CD. (May 2006). Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol. 17:1243-1252. DOI.
Grosjean J; Kiriakidis S; Reilly K; Feldmann M; Paleolog E. (17 Feb 2006). Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun. 340:984-994. DOI.
Brennan FM; Foey AD; Feldmann M. (2006). The importance of T cell interactions with macrophages in rheumatoid cytokine production. Curr Top Microbiol Immunol. 305:177-194.
Wales J; Andreakos E; Foxwell B; Williams R; Buchan G; Feldmann M. (Dec 2005). The efficacy of NF-kappa B inducing molecules as vaccine adjuvants. IMMUNOLOGY. 116:108-108.
Waterston AM; Gumbrell L; Bratt T; Waller S; Gustav-Aspland J; L'hermenier C; Bellenger K; Campbell M; et alPowles T; Highley M; Bower M; Mouritsen S; Feldmann M; Coombes RC. (Sep 2005). Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother. 54:848-857. DOI.
Sacre SM; Andreakos E; Taylor P; Feldmann M; Foxwell BM. (24 Aug 2005). Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med. 7:1-20. DOI.
Feldmann M. (Aug 2005). TNF alpha blockade : validation of importance of cytokines in medicine. INFLAMM RES. 54:S92-S92.
Feldmann M; Steinman L. (2 Jun 2005). Design of effective immunotherapy for human autoimmunity. Nature. 435:612-619. DOI.
Feldmann M; Brennan FM; Foxwell BMJ; Taylor PC; Williams RO; Maini RN. (2005). Anti-TNF therapy: Where have we got to in 2005?. JOURNAL OF AUTOIMMUNITY. 25:26-28. DOI.
Andreakos E; Sacre S; Foxwell BM; Feldmann M. (2005). The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci. 10:2478-2488.
Campbell J; Ciesielski CJ; Hunt AE; Horwood NJ; Beech JT; Hayes LA; Denys A; Feldmann M; et alBrennan FM; Foxwell BM. (1 Dec 2004). A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol. 173:6928-6937.
Cope AP; Feldmann M. (Dec 2004). Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol. 16:780-786. DOI.
Andreakos E; Foxwell B; Feldmann M. (Dec 2004). Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol Rev. 202:250-265. DOI.
Sumariwalla PF; Feldmann M; Gallily R; Mechoulam R; Tchilibon S; Fride E. (Dec 2004). Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al - Reply. ARTHRITIS RHEUM-US. 50:4079-4080. DOI.
Taylor PC; Williams RO; Feldmann M. (Dec 2004). Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol. 15:557-563. DOI.
Pertyńska-Marczewska M; Kiriakidis S; Wait R; Beech J; Feldmann M; Paleolog EM. (7 Oct 2004). Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine. 28:35-47. DOI.
Taylor PC; Feldmann M. (Aug 2004). New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. CURR OPIN PHARMACOL. 4:368-371. DOI.
Monaco C; Andreakos E; Kiriakidis S; Mauri C; Bicknell C; Foxwell B; Cheshire N; Paleolog E; et alFeldmann M. (13 Apr 2004). Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A. 101:5634-5639. DOI.
Vilcek J; Feldmann M. (Apr 2004). Historical review: cytokines as therapeutics and targets of therapeutics. Trends in Pharmacological Sciences. 4, 25:201-219.
Vilcek J; Feldmann M. (Apr 2004). Historical review: Cytokines as therapeutics and targets of therapeutics. TRENDS PHARMACOL SCI. 25:201-209. DOI.
Zhang YH; Xu J; Levin J; Hegen M; Li GD; Robertshaw H; Brennan F; Cummons T; et alClarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL. (1 Apr 2004). Identification and characterization of 4-[[4-(2-butynyloxy) phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J PHARMACOL EXP THER. 309:348-355. DOI.
Sumariwalla PF; Malfait AM; Feldmann M. (Apr 2004). P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin Exp Immunol. 136:67-75. DOI.
Waterston AM; Salway F; Andreakos E; Butler DM; Feldmann M; Coombes RC. (22 Mar 2004). TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer. 90:1279-1284. DOI.
Andreakos E; Sacre SM; Smith C; Lundberg A; Kiriakidis S; Stonehouse T; Monaco C; Feldmann M; et alFoxwell BM. (15 Mar 2004). Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood. 103:2229-2237. DOI.
Sumariwalla PF; Gallily R; Tchilibon S; Fride E; Mechoulam R; Feldmann M. (Mar 2004). A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50:985-998. DOI.
Monaco C; Andreakos E; Kiriakidis S; Feldmann M; Paleolog E. (Mar 2004). T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy. 3:35-42.
Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN. (Feb 2004). The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 18:59-80. DOI.
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN. (2004). Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?. Novartis Found Symp. 256:53-69.
Sacre SM; Andreakos E; Feldmann M; Foxwell BM. (2004). Endotoxin signaling in human macrophages: signaling via an alternate mechanism. J Endotoxin Res. 10:445-452. DOI.
Afuwape AO; Feldmann M; Paleolog EM. (Nov 2003). Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther. 10:1950-1960. DOI.
Foxwell B; Andreakos E; Brennan F; Feldmann M; Smith C; Conron M. (Nov 2003). Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. ANN RHEUM DIS. 62:90-93.
Foxwell B; Andreakos E; Brennan F; Feldmann M; Smith C; Conron M. (Nov 2003). Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann Rheum Dis. 62 Suppl 2:ii90-ii93.
Feldmann M; Maini RN. (Oct 2003). Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 9:1245-1250. DOI.
Feldmann M; Maini RN. (Oct 2003). TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. NAT MED. 9:1245-1250.
Yoshimura S; Bondeson J; Brennan FM; Foxwell BM; Feldmann M. (Aug 2003). Antigen presentation by murine dendritic cells is nuclear factor-kappa B dependent both in vitro and in vivo. Scand J Immunol. 58:165-172.
Andreakos E; Smith C; Kiriakidis S; Monaco C; de Martin R; Brennan FM; Paleolog E; Feldmann M; et alFoxwell BM. (Jul 2003). Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum. 48:1901-1912. DOI.
Kiriakidis S; Andreakos E; Monaco C; Foxwell B; Feldmann M; Paleolog E. (15 Feb 2003). VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci. 116:665-674.
Andreakos E; Smith C; Monaco C; Brennan FM; Foxwell BM; Feldmann M. (1 Feb 2003). Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood. 101:983-991. DOI.
Calder VL; Bondeson J; Brennan FM; Foxwell BMJ; Feldmann M. (2003). Antigen specific T cell downregulation by human dendritic cells following blockade of NF-kB. Scandinavian Journal of Immunology. 3, 57:261-270.
Mauri C; Feldmann M; Williams RO. (2003). Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis & Rheumatism. 3, 48:839-845.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R. (2003). Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther. 5:R317-R328. DOI.
Sumariwalla PF; Cao Y; Wu HL; Feldmann M; Paleolog EM. (2003). The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther. 5:R32-R39.
Scheinin T; Butler DM; Salway F; Scallon B; Feldmann M. (2003). Validation of the interleukin-10 knockout mouse model of colitis: anti tumour necrosis factor antibodies suppress the progression of colitis. Clinical and Experimental Immunology. 1, 133:38-43.
Andreakos E; Taylor PC; Feldmann M. (Dec 2002). Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol. 13:615-620.
Feldmann M; Andreakos E; Smith C; Bondeson J; Yoshimura S; Kiriakidis S; Monaco C; Gasparini C; et alSacre S; Lundberg A; Paleolog E; Horwood NJ; Brennan FM; Foxwell BM. (Nov 2002). Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis. 61 Suppl 2:ii13-ii18.
Kiriakidis S; Andreakos E; Monaco C; Foxwell B; Feldmann M; Paleolog E. (Sep 2002). Inhibition of VEGF in human macrophages and rheumatoid synovial cells by blockade of the NF kappa B pathway using adenoviral gene transfer. J MOL MED-JMM. 80:B3-B3.
Andreakos ET; Foxwell BM; Brennan FM; Maini RN; Feldmann M. (Aug 2002). Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13:299-313.
Ciesielski CJ; Andreakos E; Foxwell BM; Feldmann M. (Jul 2002). TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. Eur J Immunol. 32:2037-2045. DOI.
Feldmann M. (May 2002). Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2:364-371. DOI.
Monaco C; Andreakos E; Young S; Feldmann M; Paleolog E. (Apr 2002). T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol. 71:659-668.
Foey A; Green P; Foxwell B; Feldmann M; Brennan F. (2002). Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res. 4:64-70.
Feldmann M; Maini RN. (Jan 2002). Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine. 69:12-18.
Brennan FM; Hayes AL; Ciesielski CJ; Green P; Foxwell BM; Feldmann M. (Jan 2002). Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum. 46:31-41. DOI.
Horwood NJ; Smith C; Andreakos E; Quattrocchi E; Brennan FM; Feldmann M; Foxwell BM. (2002). High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets. Arthritis Res. 4 Suppl 3:S215-S225.
Maini RN; Feldmann M. (2002). How does infliximab work in rheumatoid arthritis?. Arthritis Res. 4 Suppl 2:S22-S28.
Foey AD; Feldmann M; Brennan FM. (21 Nov 2001). CD40 ligation induces macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 MAPK-pathways. Cytokine. 16:131-142. DOI.
Smith C; Andreakos E; Crawley JB; Brennan FM; Feldmann M; Foxwell BM. (15 Nov 2001). NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol. 167:5895-5903.
Foxwell BMJ; Yoshimura S; Bondeson J; Brennan FM; Feldmann M. (Nov 2001). High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach. ANN RHEUM DIS. 60:III13-III17.
Foxwell BM; Yoshimura S; Bondeson J; Brennan FM; Feldmann M. (Nov 2001). High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach. Ann Rheum Dis. 60 Suppl 3:iii13-iii17.
Feldmann M. (Oct 2001). Immunotherapy - Editorial overview. CURR OPIN IMMUNOL. 13:595-596.
Feldmann M. (Sep 2001). Pathogenesis of arthritis: recent research progress. Nat Immunol. 2:771-773. DOI.
Ballara S; Taylor PC; Reusch P; Marmé D; Feldmann M; Maini RN; Paleolog EM. (Sep 2001). Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44:2055-2064. DOI.
Conron M; Bondeson J; Pantelidis P; Beynon HL; Feldmann M; duBois RM; Foxwell BM. (Aug 2001). Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways. Am J Respir Cell Mol Biol. 25:141-149.
Feldmann M. (Jun 2001). Gene therapy for rheumatoid arthritis?. J CLIN INVEST. 107:1353-1353.
Yoshimura S; Bondeson J; Brennan FM; Foxwell BM; Feldmann M. (Jun 2001). Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol. 31:1883-1893.
Quattrocchi E; Dallman MJ; Dhillon AP; Quaglia A; Bagnato G; Feldmann M. (15 May 2001). Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol. 166:5970-5978.
Feldmann M; Brennan F; Bondeson J; Paleolog E; Foxwell B; Maini R. (May 2001). Analysis of cytokine expression in rheumatoid synovium has provided new insights into the pathogenesis of rheumatoid arthritis and new therapeutic opportunities. Transplant Proc. 33:2085-2086.
Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M. (May 2001). Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44:1215-1224. DOI.
Yoshimura S; Bondeson J; Foxwell BM; Brennan FM; Feldmann M. (May 2001). Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol. 13:675-683.
Yamamoto AM; Chernajovsky Y; Lepault F; Podhajcer O; Feldmann M; Bach JF; Chatenoud L. (15 Apr 2001). The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy. J Immunol. 166:4973-4980.
Croxford JL; Feldmann M; Chernajovsky Y; Baker D. (15 Mar 2001). Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immunol. 166:4124-4130.
Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP. (Feb 2001). Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum. 44:451-462. DOI.
Monaco C; Andreakos E; Feldmann M; Paleolog E. (Feb 2001). Inhibition of tissue factor induction by blockade of the nuclear factor-kappa B pathway in human macrophages and endothelial cells using adenoviral gene transfer: Nuclear factor-kappa B as a potential therapeutic target for plaque stabilization. J AM COLL CARDIOL. 37:289A-289A.
Feldmann M; Maini RN. (2001). Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol. 19:163-196. DOI.
Monaco C; Young S; Paleolog E; Maseri A; Feldmann M. (2001). Cellular mechanisms of regulation of the inflammatory response in atherosclerosis: the role of cell contact-mediated signalling. Ital Heart J. 2:339-343.
Feldmann M; Maini RN; Bondeson J; Taylor P; Foxwell BM; Brennan FM. (2001). Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol. 490:119-127.
Foxwell BMJ; Yoshimura S; Bondeson J; Brennan FM; Feldmann M. (2001). High efficiency gene transfer is an efficient way of defining therapeutic targets:a functional genomics approach. Ann Rheum Dis. 60:13-17.
Quattrocchi E; Feldmann M. (2001). Recombinant adenovirus-mediated gene transfer suppresses experimental arthritis. Reumatismo. 1, 53:46-54.
Feldmann M; Brennan FM; Foxwell BM; Maini RN. (2001). The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 3:188-199.
Bondeson J; Feldmann M; Maini RN. (2001). Tumour necrosis factor as a therapeutic target: from the laboratory to the clinic. The Immunologist. 6, 8:136-140.
Williams RO; Marinova-Mutafchieva L; Feldmann M; Maini RN. (15 Dec 2000). Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol. 165:7240-7245.
Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M. (Dec 2000). Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. Nihon Rinsho Meneki Gakkai Kaishi. 23:487-489.
Lipsky PE; van der Heijde DMFM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; et alEmery P; Feldmann M; Harriman GR; Maini RN; Anti-Tumor Necrosis Factor Trial. (30 Nov 2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis. NEW ENGL J MED. 343:1594-1602.
Foxwell BMJ; Bondeson J; Brennan F; Feldmann M. (Nov 2000). Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NF kappa B in tumour necrosis factor production. ANN RHEUM DIS. 59:54-59.
Foxwell BM; Bondeson J; Brennan F; Feldmann M. (Nov 2000). Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production. Ann Rheum Dis. 59 Suppl 1:i54-i59.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN. (Nov 2000). Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2383-2390. DOI.
Williams RO; Feldmann M; Maini RN. (Nov 2000). Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis. 59 Suppl 1:i75-i80.
Feldmann M; Miotla J; Paleolog E; Williams R; Malfait AM; Taylor P; Brennan FM; Maini RN. (Nov 2000). Future prospects for anti-cytokine treatment. Ann Rheum Dis. 59 Suppl 1:i119-i122.
Bondeson J; Feldmann M; Maini RN. (Nov 2000). TNF as a therapeutic target. IMMUNOLOGIST. 8:136-140.
Foey AD; Feldmann M; Brennan FM. (Oct 2000). Route of monocyte differentiation determines their cytokine production profile: CD40 ligation induces interleukin 10 expression. Cytokine. 12:1496-1505. DOI.
Bondeson J; Brennan F; Foxwell B; Feldmann M. (Sep 2000). Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent. J Rheumatol. 27:2078-2089.
Malfait AM; Gallily R; Sumariwalla PF; Malik AS; Andreakos E; Mechoulam R; Feldmann M. (15 Aug 2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 97:9561-9566. DOI.
Quattrocchi E; Dallman MJ; Feldmann M. (Aug 2000). Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. 43:1688-1697. DOI.
Miotla J; Maciewicz R; Kendrew J; Feldmann M; Paleolog E. (Aug 2000). Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest. 80:1195-1205.
Lindsay JO; Feldmann M; Hodgson HJ; Brennan FM. (Apr 2000). The immunoregulatory role of interleukin-10 in Crohn's disease (CD) cell cultures. GASTROENTEROLOGY. 118:A110-A110.
Lindsay JO; Ciesielski CJ; Feldmann M; Brennan FM; Hodgson HJ. (Apr 2000). The stable infection of epithelial cell lines and primary rabbit colon cells with an adenovirus encoding murine interleukin-10 (mIL-10) generates bioactive cytokine at therapeutic concentrations. GASTROENTEROLOGY. 118:A584-A584.
Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN. (Mar 2000). A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum. 43:638-644. DOI.
Croxford JL; Triantaphyllopoulos KA; Neve RM; Feldmann M; Chernajovsky Y; Baker D. (2000). Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. Journal of Immunology. 164:2776-2781.
Taylor PC; Peters AM; Paleolog E; Chapman PT; Elliott MJ; McCloskey R; Feldmann M; Maini RN. (Jan 2000). Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43:38-47. DOI.
Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; et alHarriman G; Feldmann M; Lipsky P. (4 Dec 1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 354:1932-1939.
Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M. (Nov 1999). Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 58 Suppl 1:I56-I60.
Williams RO; Malfait AM; Butler DM; Walmsley MJ; Feldmann M; Maini RN. (Nov 1999). Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin Exp Rheumatol. 17:S115-S120.
Webb LM; Foxwell BM; Feldmann M. (Nov 1999). Putative role for interleukin-7 in the maintenance of the recirculating naive CD4+ T-cell pool. Immunology. 98:400-405.
Feldmann M; Bondeson J; Brennan FM; Foxwell BM; Maini RN. (Nov 1999). The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?. Ann Rheum Dis. 58 Suppl 1:I27-I31.
Feldmann M; Maini RN. (Nov 1999). The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 38 Suppl 2:3-7.
Nedvetzki S; Walmsley M; Alpert E; Williams RO; Feldmann M; Naor D. (Aug 1999). CD44 involvement in experimental collagen-induced arthritis (CIA). JOURNAL OF AUTOIMMUNITY. 13:39-47.
Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; et alEberl G; deWoody K; Feldmann M; Maini RN. (1 Aug 1999). Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 163:1521-1528.
Quattrocchi E; Walmsley M; Browne K; Williams RO; Marinova-Mutafchieva L; Buurman W; Butler DM; Feldmann M. (15 Jul 1999). Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol. 163:1000-1009.
Butler DM; Malfait AM; Maini RN; Brennan FM; Feldmann M. (Jul 1999). Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol. 29:2205-2212. DOI.
Malfait AM; Malik AS; Marinova-Mutafchieva L; Butler DM; Maini RN; Feldmann M. (15 May 1999). The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol. 162:6278-6283.
Bondeson J; Foxwell B; Brennan F; Feldmann M. (11 May 1999). Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A. 96:5668-5673.
Bondeson J; Browne KA; Brennan FM; Foxwell BM; Feldmann M. (1 Mar 1999). Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. J Immunol. 162:2939-2945.
Kissonerghis M; Daly G; Feldmann M; Chernajovsky Y. (Feb 1999). The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer. Mol Immunol. 36:125-134.
Dalum I; Butler DM; Jenson MR; Hindersson P; Steinaa L; Waterson AM; Grell SN; Feldmann M; et alElsner HI; Mouritsen S. (1999). Therapeutic antibodies induced by immunization against TNF alpha. Nature Biotechnology. 17:666-669.
Croxford JL; O'Neill JK; Ali RR; Browne K; Byrnes AP; Dallman MJ; Wood MJA; Feldmann M; et alBaker D. (Dec 1998). Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. EUR J IMMUNOL. 28:3904-3916.
Gould DJ; Foxwell BM; Feldmann M; Chernajovsky Y. (Dec 1998). Potentiation of TNF-alpha toxicity by conjugation with ricin A-chain. Cytokine. 10:931-939. DOI.
Williams RO; Mauri C; Mason LJ; Marinova-Mutafchieva L; Ross SE; Feldmann M; Maini RN. (Oct 1998). Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum. 41:1806-1812. DOI.
Walmsley M; Butler DM; Marinova-Mutafchieva L; Feldmann M. (Sep 1998). An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology. 95:31-37.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M. (Sep 1998). Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein. Eur Cytokine Netw. 9:255-262.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; et alElliott MJ; Woody JN; Schaible TF; Feldmann M. (Sep 1998). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552-1563. DOI.
Hermann JA; Hall MA; Maini RN; Feldmann M; Brennan FM. (Aug 1998). Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 41:1388-1397. DOI.
Foxwell B; Browne K; Bondeson J; Clarke C; de Martin R; Brennan F; Feldmann M. (7 Jul 1998). Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A. 95:8211-8215.
Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN. (Jul 1998). Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41:1258-1265. DOI.
Sanz MJ; Marinova-Mutafchieva L; Green P; Lobb RR; Feldmann M; Nourshargh S. (1 Jun 1998). IL-4-induced eosinophil accumulation in rat skin is dependent on endogenous TNF-alpha and alpha 4 integrin/VCAM-1 adhesion pathways. J Immunol. 160:5637-5645.
Malfait AM; Butler DM; Presky DH; Maini RN; Brennan FM; Feldmann M. (Feb 1998). Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol. 111:377-383.
Foey AD; Parry SL; Williams LM; Feldmann M; Foxwell BM; Brennan FM. (15 Jan 1998). Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol. 160:920-928.
Feldmann M; Charles P; Taylor P; Maini RN. (1998). Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol. 20:211-228.
Feldmann M; Brennan FM; Maini R. (1998). Cytokines in autoimmune disorders. Int Rev Immunol. 17:217-228.
Feldmann M; Maini RN. (1998). Rheumatoid arthritis: introduction. Springer Semin Immunopathol. 20:3-4.
Brennan FM; Maini RN; Feldmann M. (1998). Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol. 20:133-147.
Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M. (15 Dec 1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 159:6253-6259.
Horsfall AC; Butler DM; Marinova L; Warden PJ; Williams RO; Maini RN; Feldmann M. (1 Dec 1997). Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol. 159:5687-5696.
Sanz MJ; Hartnell A; Chisholm P; Williams C; Davies D; Weg VB; Feldmann M; Bolanowski MA; et alLobb RR; Nourshargh S. (15 Nov 1997). Tumor necrosis factor alpha-induced eosinophil accumulation in rat skin is dependent on alpha4 integrin/vascular cell adhesion molecule-1 adhesion pathways. Blood. 90:4144-4152.
Butler DM; Malfait AM; Mason LJ; Warden PJ; Kollias G; Maini RN; Feldmann M; Brennan FM. (15 Sep 1997). DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol. 159:2867-2876.
Davis D; Charles PJ; Potter A; Feldmann M; Maini RN; Elliott MJ. (Sep 1997). Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol. 36:950-956.
Feldmann M; Brennan F; Paleolog E; Taylor P; Maini RN. (Sep 1997). Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. Eur Cytokine Netw. 8:297-300.
Cohen SB; Crawley JB; Kahan MC; Feldmann M; Foxwell BM. (Sep 1997). Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 92:1-5.
Taylor PC; Chapman P; Elliott MJ; Schaible TF; Peters AM; Feldmann M; Maini RN. (Sep 1997). Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNF alpha therapy. ARTHRITIS RHEUM. 40:297-297.
Fiehn C; Paleolog EM; Feldmann M. (Aug 1997). Selective enhancement of endothelial cell VCAM-1 expression by interleukin-10 in the presence of activated leucocytes. Immunology. 91:565-571.
Cohen SB; Parry SL; Feldmann M; Foxwell B. (15 Jun 1997). Autocrine and paracrine regulation of human T cell IL-10 production. J Immunol. 158:5596-5602.
Giovannoni G; Lai M; Thorpe J; Kidd D; Chamoun V; Thompson AJ; Miller DH; Feldmann M; et alThompson EJ. (Jun 1997). Longitudinal study of soluble adhesion molecules in multiple sclerosis: Correlation with gadolinium enhanced magnetic resonance Imaging. NEUROLOGY. 48:1557-1565.
Brennan FM; Browne KA; Green PA; Jaspar JM; Maini RN; Feldmann M. (Jun 1997). Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol. 36:643-650.
Parry SL; Sebbag M; Feldmann M; Brennan FM. (15 Apr 1997). Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol. 158:3673-3681.
Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M. (Apr 1997). TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS. 105:257-263.
Sebbag M; Parry SL; Brennan FM; Feldmann M. (Mar 1997). Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol. 27:624-632. DOI.
Marinova-Mutafchieva L; Williams RO; Mason LJ; Mauri C; Feldmann M; Maini RN. (Mar 1997). Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol. 107:507-512.
Webb LM; Foxwell BM; Feldmann M. (Mar 1997). Interleukin-7 activates human naive CD4+ cells and primes for interleukin-4 production. Eur J Immunol. 27:633-640. DOI.
Feldmann M; Elliott MJ; Woody JN; Maini RN. (1997). Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol. 64:283-350.
Brennan FM; Feldmann M. (Dec 1996). Cytokines in autoimmunity. Curr Opin Immunol. 8:872-877.
Feldmann M. (Dec 1996). What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?. Int Arch Allergy Immunol. 111:362-365.
Feldmann M. (Nov 1996). The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. J R Coll Physicians Lond. 30:560-570.
Webb LM; Walmsley MJ; Feldmann M. (Oct 1996). Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol. 26:2320-2328. DOI.
Maini RN; Feldmann M. (21 Sep 1996). Cytokine therapy in rheumatoid arthritis. LANCET. 348:824-825.
Paleolog EM; Hunt M; Elliott MJ; Feldmann M; Maini RN; Woody JN. (Jul 1996). Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 39:1082-1091.
Mauri C; Williams RO; Walmsley M; Feldmann M. (Jul 1996). Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol. 26:1511-1518. DOI.
Williams LM; Gibbons DL; Gearing A; Maini RN; Feldmann M; Brennan FM. (15 Jun 1996). Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 97:2833-2841. DOI.
Feldmann M; Brennan FM; Maini RN. (3 May 1996). Rheumatoid arthritis. Cell. 85:307-310.
Neve R; Kissonerghis M; Clark J; Feldmann M; Chernajovsky Y. (May 1996). Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine. 8:365-370. DOI.
Walmsley M; Katsikis PD; Abney E; Parry S; Williams RO; Maini RN; Feldmann M. (Mar 1996). Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 39:495-503.
Cohen SB; Webb LM; Feldmann M. (Mar 1996). The method of deriving human T-cell clones alters the proportion of IL-10-producing cells. Immunology. 87:343-347.
Norman KE; Williams TJ; Feldmann M; Rossi AG. (Feb 1996). Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions. Br J Pharmacol. 117:471-478.
Quaratino S; Feldmann M; Dayan CM; Acuto O; Londei M. (1 Feb 1996). Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. J Exp Med. 183:349-358.
Brookes SM; Cohen SB; Price EJ; Webb LM; Feldmann M; Maini RN; Venables PJ. (Feb 1996). T cell clones from a Sjögren's syndrome salivary gland biopsy produce high levels of IL-10. Clin Exp Immunol. 103:268-272.
Feldmann M; Brennan FM; Maini RN. (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 14:397-440. DOI.
Chernajovsky Y; Adams G; Podhajcer OL; Mueller GM; Robbins PD; Feldmann M. (Dec 1995). Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther. 2:731-735.
Webb LM; Feldmann M. (1 Nov 1995). Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Blood. 86:3479-3486.
Clarke CJ; Taylor-Fishwick DA; Hales A; Chernajovsky Y; Sugamura K; Feldmann M; Foxwell BM. (Oct 1995). Interleukin-4 inhibits kappa light chain expression and NF kappa B activation but not I kappa B alpha degradation in 70Z/3 murine pre-B cells. Eur J Immunol. 25:2961-2966. DOI.
Feldmann M; Brennan FM; Elliott MJ; Williams RO; Maini RN. (7 Sep 1995). TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann N Y Acad Sci. 766:272-278.
BRENNAN FM; BUTLER DM; MIANI N; FELDMANN M. (Sep 1995). MODULATION OF PROINFLAMMATORY CYTOKINE RELEASE IN RHEUMATOID SYNOVIAL-MEMBRANE CELL-CULTURES WITH AN ANTI TNF-ALPHA MONOCLONAL - COMPARISON WITH BLOCKADE OF IL-1 USING THE RECOMBINANT IL-1 RECEPTOR ANTAGONIST. ARTHRITIS RHEUM. 38:1483-1483.
BRENNAN FM; WILLIAMS L; GIBBONS DL; MAINI RN; FELDMANN M. (Sep 1995). PROTEOLYTIC CLEAVAGE OF THE P55 AND P75 TNF RECEPTOR IS BLOCKED BY A SYNTHETIC METALLOPROTEINASE INHIBITOR - INDEPENDENT OF ITS EFFECT ON TNF-ALPHA PROCESSING. ARTHRITIS RHEUM. 38:1143-1143.
Katsikis PD; Cohen SB; Londei M; Feldmann M. (Aug 1995). Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-gamma or IL-2 determines their function. Int Immunol. 7:1287-1294.
Maini RN; Elliott MJ; Brennan FM; Feldmann M. (Aug 1995). Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol. 101:207-212.
Londei M; Dayan C; Feldmann M; Acuto O; Quaratino S. (7 Jul 1995). Human autoreactive T-cell clones show flexibility in recognizing overlapping microepitopes, but inflexibility in T-cell receptor usage. Ann N Y Acad Sci. 756:345-348.
Chu NR; Quaratino S; Feldmann M; Londei M. (Jul 1995). Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line. Int Immunol. 7:1057-1063.
Cohen SB; Katsikis PD; Chu CQ; Thomssen H; Webb LM; Maini RN; Londei M; Feldmann M. (Jul 1995). High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum. 38:946-952.
Mullins RJ; Cohen SB; Webb LM; Chernajovsky Y; Dayan CM; Londei M; Feldmann M. (Jul 1995). Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. J Clin Invest. 96:30-37. DOI.
Butler DM; Maini RN; Feldmann M; Brennan FM. (Jul 1995). Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw. 6:225-230.
Phillips WG; Feldmann M; Breathnach SM; Brennan FM. (Jul 1995). Modulation of the IL-1 cytokine network in keratinocytes by intracellular IL-1 alpha and IL-1 receptor antagonist. Clin Exp Immunol. 101:177-182.
Brennan FM; Gibbons DL; Cope AP; Katsikis P; Maini RN; Feldmann M. (Jul 1995). TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol. 42:158-165.
Brennan FM; Maini RN; Feldmann M. (Apr 1995). Cytokine expression in chronic inflammatory disease. Br Med Bull. 51:368-384.
Chernajovsky Y; Feldmann M; Maini RN. (Apr 1995). Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Br Med Bull. 51:503-516.
Katsikis PD; Cohen SB; Murison JG; Uren J; Hibbart LM; Callard RE; Di Padova F; Feldmann M; et alLondei M. (Apr 1995). Human alpha beta T-cell receptor CD4-CD8 T-cell clones are predominantly Th0-like. Immunology. 84:501-504.
Maini RN; Elliott MJ; Brennan FM; Williams RO; Chu CQ; Paleolog E; Charles PJ; Taylor PC; et alFeldmann M. (Apr 1995). Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 144:195-223.
Williams RO; Ghrayeb J; Feldmann M; Maini RN. (Mar 1995). Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology. 84:433-439.
Elliott MJ; Feldmann M; Maini RN. (Feb 1995). TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol. 17:141-145.
Feldmann M; Brennan FM; Williams RO; Elliott MJ; Maini RN. (1995). Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. J Inflamm. 47:90-96.
Weg VB; Walsh DT; Faccioli LH; Williams TJ; Feldmann M; Nourshargh S. (Jan 1995). LPS-induced 111In-eosinophil accumulation in guinea-pig skin: evidence for a role for TNF-alpha. Immunology. 84:36-40.
Brennan FM; Cope AP; Katsikis P; Gibbons DL; Maini RN; Feldmann M. (1995). Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis. Chem Immunol. 60:48-60.
Cope AP; Aderka D; Wallach D; Kahan M; Chu NR; Brennan FM; Feldmann M. (Jan 1995). Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology. 84:21-30.
Cohen SB; Katsikis PD; Feldmann M; Londei M. (Nov 1994). IL-10 enhances expression of the IL-2 receptor alpha chain on T cells. Immunology. 83:329-332.
Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M. (Nov 1994). Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin Exp Rheumatol. 12 Suppl 11:S63-S66.
Butler DM; Scallon B; Meager A; Kissonerghis M; Corcoran A; Chernajovsky Y; Feldmann M; Ghrayeb J; et alBrennan FM. (Nov 1994). TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine. 6:616-623.
ELLIOTT MJ; MAINI RN; FELDMANN M; KALDEN JR; ANTONI C; SMOLEN JS; LEEB B; BREEDVELD FC; et alMACFARLANE JD; BIJL H; WOODY JN. (22 Oct 1994). RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS. LANCET. 344:1105-1110.
Elliott MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Bijl H; Woody JN. (22 Oct 1994). Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 344:1125-1127.
Paleolog EM; Delasalle SA; Buurman WA; Feldmann M. (15 Oct 1994). Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 84:2578-2590.
Feldmann M; Elliott MJ; Brennan FM; Maini RN. (Oct 1994). Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis. J Interferon Res. 14:299-300.
Butler DM; Feldmann M; Di Padova F; Brennan FM. (Sep 1994). p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw. 5:441-448.
Corcoran AE; Barrett K; Turner M; Brown A; Kissonerghis AM; Gadnell M; Gray PW; Chernajovsky Y; et alFeldmann M. (1 Aug 1994). Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. Eur J Biochem. 223:831-840.
Cope AP; Londei M; Chu NR; Cohen SB; Elliott MJ; Brennan FM; Maini RN; Feldmann M. (Aug 1994). Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 94:749-760. DOI.
Gibbons DL; Rowe M; Cope AP; Feldmann M; Brennan FM. (Aug 1994). Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol. 24:1879-1885. DOI.
Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN. (Aug 1994). TNF alpha as a therapeutic target in rheumatoid arthritis. Circ Shock. 43:179-184.
Mullins RJ; Chernajovsky Y; Dayan C; Londei M; Feldmann M. (1 Jun 1994). Transfection of thyroid autoantigens into EBV-transformed B cell lines. Recognition by Graves' disease thyroid T cells. J Immunol. 152:5572-5580.
Katsikis PD; Chu CQ; Brennan FM; Maini RN; Feldmann M. (1 May 1994). Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 179:1517-1527.
Williams RO; Mason LJ; Feldmann M; Maini RN. (29 Mar 1994). Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A. 91:2762-2766.
Baker D; Butler D; Scallon BJ; O'Neill JK; Turk JL; Feldmann M. (1994). Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. European Journal of Immunology. 24:2040-2048.
Maini RN; Elliott MJ; Charles PJ; Feldmann M. (1994). Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol. 16:327-336.
Joyce DA; Gibbons DP; Green P; Steer JH; Feldmann M; Brennan FM. (1994). Two inhibitors of pro-inflammatory cytokine release, IL-10 and IL-4, have contrasting effects on release of soluble p75 TNF receptor by cultured monocytes. European Journal of Immunology. 24:2699-2705.
ELLIOTT MJ; MAINI RN; FELDMANN M; LONGFOX A; CHARLES P; KATSIKIS P; BRENNAN FM; WALKER J; et alBIJL H; GHRAYEB J; WOODY JN. (Dec 1993). TREATMENT OF RHEUMATOID-ARTHRITIS WITH CHIMERIC MONOCLONAL-ANTIBODIES TO TUMOR-NECROSIS-FACTOR-ALPHA. ARTHRITIS RHEUM. 36:1681-1690.
Paleolog EM; Katsikis P; Harris G; Daddona P; Dalesandro MR; Kinney CS; Woody JN; Feldmann M. (Nov 1993). Antilipid A monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. Cytokine. 5:570-577.
Kristensen M; Chu CQ; Eedy DJ; Feldmann M; Brennan FM; Breathnach SM. (Nov 1993). Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol. 94:354-362.
Soomro S; Taylor P; Shepard HM; Feldmann M; Sinnett HD; Shousha S. (19 Aug 1993). c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study. Int J Cancer. 55:63-65.
ADERKA D; WYSENBEEK A; ENGELMANN H; COPE AP; BRENNAN F; MOLAD Y; HORNIK V; LEVO Y; et alMAINI RN; FELDMANN M; WALLACH D. (Aug 1993). CORRELATION BETWEEN SERUM LEVELS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS. ARTHRITIS RHEUM. 36:1111-1120.
Dayan CM; Chu NR; Londei M; Rapoport B; Feldmann M. (1 Aug 1993). T cells involved in human autoimmune disease are resistant to tolerance induction. J Immunol. 151:1606-1613.
Haworth C; O'Reilly SM; Chu E; Rustin GJ; Feldmann M. (Jun 1993). Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies. Br J Cancer. 67:1346-1350.
Cope AP; Gibbons DL; Aderka D; Foxwell BM; Wallach D; Maini RN; Feldmann M; Brennan FM. (May 1993). Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine. 5:205-212.
Williams RO; Williams DG; Feldmann M; Maini RN. (May 1993). Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol. 92:323-327.
KRISTENSEN M; DELEURAN B; BRENNAN F; FELDMANN M; THESTRUPPEDERSEN K. (Apr 1993). DETECTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN (IRAP), IL-ALPHA, TNF-ALPHA, THEIR RECEPTORS AND IL-8 IN ALLERGIC PATCH TEST REACTIONS. J INVEST DERMATOL. 100:468-468.
Maini RN; Brennan FM; Williams R; Chu CQ; Cope AP; Gibbons D; Elliott M; Feldmann M. (Mar 1993). TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol. 11 Suppl 8:S173-S175.
FELDMANN M; BRENNAN FM; MAINI RN. (Feb 1993). CYTOKINES IN RHEUMATOID-ARTHRITIS - IS TNF-ALPHA OF MAJOR IMPORTANCE. CLIN EXP ALLERGY. 23:35-35.
GIBBONS DL; COPE AP; FELDMANN M; BRENNAN FM. (26 Jan 1993). DIFFERENTIAL REGULATION OF TUMOR-NECROSIS-FACTOR RECEPTORS BY IMMUNOSUPPRESSIVE CYTOKINES. J CELL BIOCHEM. 145-145.
BRENNAN FM; GIBBONS DL; COPE AP; CHU A; MAINI RN; FELDMANN M. (26 Jan 1993). EXPRESSION OF SURFACE P55 AND P75 TNF RECEPTORS IN RHEUMATOID-ARTHRITIS. J CELL BIOCHEM. 144-144.
BUTLER D; KISSONERGHIS M; SCALLON B; GHRAYEB J; BRENNAN F; FELDMANN M. (26 Jan 1993). INHIBITION OF TNF MEDIATED CYTOTOXICITY IN HUMAN AND MOUSE CELLS BY MONOMERIC SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR P55 AND A CHIMERIC RECEPTOR-1GG. J CELL BIOCHEM. 144-144.
HAWRYLOWICZ C; SADEGHI R; FELDMANN M; PALEOLOG E. (26 Jan 1993). UP-REGULATION OF HLA-DQ EXPRESSION BY GM-CSF, OR IL-3, WITH DEXAMETHASONE ON HUMAN MONOCYTES BUT NOT ENDOTHELIAL-CELLS. J CELL BIOCHEM. 133-133.
Brennan FM; Feldmann M. (Dec 1992). Cytokines in autoimmunity. Curr Opin Immunol. 4:754-759.
Chu CQ; Field M; Andrew E; Haskard D; Feldmann M; Maini RN. (Dec 1992). Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Clin Exp Immunol. 90:522-529.
Deleuran BW; Chu CQ; Field M; Brennan FM; Katsikis P; Feldmann M; Maini RN. (Dec 1992). Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 31:801-809.
Paleolog EM; Aluri GR; Feldmann M. (Nov 1992). Contrasting effects of interferon gamma and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor alpha. Cytokine. 4:470-478.
Foxwell BM; Barrett K; Feldmann M. (Nov 1992). Cytokine receptors: structure and signal transduction. Clin Exp Immunol. 90:161-169.
Williams RO; Feldmann M; Maini RN. (15 Oct 1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 89:9784-9788.
Chu CQ; Field M; Allard S; Abney E; Feldmann M; Maini RN. (Oct 1992). Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol. 31:653-661.
KRISTENSEN M; DELEURAN B; EEDY DJ; FELDMANN M; BREATHNACH SM; BRENNAN FM. (Oct 1992). DISTRIBUTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN (IRAP), INTERLEUKIN-1 RECEPTOR, AND INTERLEUKIN 1-ALPHA IN NORMAL AND PSORIATIC SKIN - DECREASED EXPRESSION OF IRAP IN PSORIATIC LESIONAL EPIDERMIS. BRIT J DERMATOL. 127:305-311.
Cope AP; Aderka D; Doherty M; Engelmann H; Gibbons D; Jones AC; Brennan FM; Maini RN; et alWallach D; Feldmann M. (Oct 1992). Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35:1160-1169.
Deleuran BW; Chu CQ; Field M; Brennan FM; Mitchell T; Feldmann M; Maini RN. (Oct 1992). Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 35:1170-1178.
CHU CO; DELEURAN BW; FIELD M; BRENNAN FM; MITCHELL T; FELDMANN M; MAINI RN. (Sep 1992). INCREASED EXPRESSION OF TNF RECEPTORS IN THE SYNOVIAL TISSUE IN RHEUMATOID-ARTHRITIS. ARTHRITIS RHEUM. 35:S174-S174.
Arnaout AH; Dawson PM; Soomro S; Taylor P; Theodorou NA; Feldmann M; Fendly BM; Shepard HM; et alShousha S. (Aug 1992). HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J Clin Pathol. 45:726-727.
Brennan FM; Gibbons DL; Mitchell T; Cope AP; Maini RN; Feldmann M. (Jul 1992). Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol. 22:1907-1912. DOI.
Sadeghi R; Hawrylowicz CM; Chernajovsky Y; Feldmann M. (Jul 1992). Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-gamma) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes. Cytokine. 4:287-297.
Sadeghi R; Feldmann M; Hawrylowicz C. (Jul 1992). Upregulation of HLA class II, but not intercellular adhesion molecule 1 (ICAM-1) by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-3 (IL-3) in synergy with dexamethasone. Eur Cytokine Netw. 3:373-380.
Brennan FM; Maini RN; Feldmann M. (May 1992). TNF alpha--a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 31:293-298.
KRISTENSEN M; DELEURAN B; EEDY DJ; FELDMANN M; BREATHNACH SM; BRENNAN FM. (Apr 1992). DISTRIBUTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN (IRAP), INTERLEUKIN-1 RECEPTOR (IL-1R), AND INTERLEUKIN-1-ALPHA (IL-1-ALPHA) IN NORMAL AND PSORIATIC SKIN. J INVEST DERMATOL. 98:533-533.
KRISTENSEN M; CHU CQ; EEDY DJ; FELDMANN M; BREATHNACH SM; BRENNAN FM. (Apr 1992). LOCALIZATION OF TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) AND ITS RECEPTORS IN NORMAL AND PSORIATIC SKIN. J INVEST DERMATOL. 98:533-533.
Feldmann M; Dayan C; Rapoport B; Londei M. (Apr 1992). T cell activation and antigen presentation in human thyroid autoimmunity. J Autoimmun. 5 Suppl A:115-121.
Zheng RQ; Abney ER; Chu CQ; Field M; Maini RN; Lamb JR; Feldmann M. (Mar 1992). Detection of in vivo production of tumour necrosis factor-alpha by human thyroid epithelial cells. Immunology. 75:456-462.
Feldmann M; June CH; McMichael A; Maini R; Simpson E; Woody JN. (Mar 1992). T-cell-targeted immunotherapy. Immunol Today. 13:84-85.
GIBBONS DL; MITCHELL TJ; COPE AP; MAINI RN; BRENNAN FM; FELDMANN M. (1992). INCREASED EXPRESSION OF TUMOR-NECROSIS-FACTOR RECEPTORS ON CELLS ISOLATED FROM RHEUMATOID-ARTHRITIS SYNOVIAL JOINTS. BRIT J RHEUMATOL. 31:211-211.
COPE AP; ADERKA D; DOHERTY M; GIBBONS DL; BRENNAN FM; MAINI RN; WALLACH D; FELDMANN M. (1992). SOLUBLE TUMOR-NECROSIS-FACTOR (TNF) RECEPTORS ARE INCREASED IN THE SERA AND SYNOVIAL-FLUIDS OF PATIENTS WITH RHEUMATIC DISEASES. BRIT J RHEUMATOL. 31:211-211.
CORCORAN AE; TURNER M; GRAY PW; BROWN A; KISSONERGHIS AM; CHERNAJOVSKY Y; FELDMANN M. (1992). STRUCTURE-FUNCTION STUDIES ON THE EXTRACELLULAR DOMAIN OF THE HUMAN P55 TNF RECEPTOR. BRIT J RHEUMATOL. 31:112-112.
Dayan CM; Feldmann M; Rapoport B; Londei M. (1992). Autoimmune thyroiditis and targeted anti-T cell immunotherapy in man. Autoimmunity. 11:189-198.
Shalaby MR; Shepard HM; Presta L; Rodrigues ML; Beverley PCL; Feldmann M; Carter P. (1992). Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. Journal of Expermental Medicine. 175:217-225.
SHALABY MR; SHEPARD HM; PRESTA L; RODRIGUES ML; BEVERLEY PCL; FELDMANN M; CARTER P. (1 Jan 1992). DEVELOPMENT OF HUMANIZED BISPECIFIC ANTIBODIES REACTIVE WITH CYTOTOXIC LYMPHOCYTES AND TUMOR-CELLS OVEREXPRESSING THE HER2 PROTOONCOGENE. J EXP MED. 175:217-225.
Feldmann M; Brennan FM; Williams RO; Cope AP; Gibbons DL; Katsikis PD; Maini RN. (1992). Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res. 4:247-255.
Feldmann M; Dayan C; Grubeck-Loebenstein B; Rapoport B; Londei M. (1992). Mechanism of Graves thyroiditis: implications for concepts and therapy of autoimmunity. Int Rev Immunol. 9:91-106.
NAOR D; ESSERY G; TARCIC N; KAHAN M; FELDMANN M. (30 Dec 1991). REGULATORY INTERACTIONS AMONG AUTOLOGOUS T-CELL CLONES - HUMAN BIFUNCTIONAL T-CELL CLONES REGULATE THE ACTIVITY OF AN AUTOLOGOUS T-CELL CLONE. ANN NY ACAD SCI. 636:135-146.
Chu CQ; Field M; Abney E; Zheng RQ; Allard S; Feldmann M; Maini RN. (Dec 1991). Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol. 86:380-386.
Haworth C; Brennan FM; Chantry D; Turner M; Maini RN; Feldmann M. (Oct 1991). Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 21:2575-2579. DOI.
Hawrylowicz CM; Howells GL; Feldmann M. (1 Oct 1991). Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med. 174:785-790.
Chu CQ; Field M; Feldmann M; Maini RN. (Sep 1991). Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34:1125-1132.
Dayan CM; Londei M; Corcoran AE; Grubeck-Loebenstein B; James RF; Rapoport B; Feldmann M. (15 Aug 1991). Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci U S A. 88:7415-7419.
Barrett K; Taylor-Fishwick DA; Cope AP; Kissonerghis AM; Gray PW; Feldmann M; Foxwell BM. (Jul 1991). Cloning, expression and cross-linking analysis of the murine p55 tumor necrosis factor receptor. Eur J Immunol. 21:1649-1656. DOI.
Turner M; Chantry D; Katsikis P; Berger A; Brennan FM; Feldmann M. (Jul 1991). Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol. 21:1635-1639. DOI.
Partridge M; Chantry D; Turner M; Feldmann M. (May 1991). Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. J Invest Dermatol. 96:771-776.
Soomro S; Shousha S; Taylor P; Shepard HM; Feldmann M. (Mar 1991). c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol. 44:211-214.
Kontiainen S; Toomath R; Lowder J; Feldmann M. (Mar 1991). Selective activation of T cells in newly diagnosed insulin-dependent diabetic patients: evidence for heterogeneity of T cell receptor usage. Clin Exp Immunol. 83:347-351.
FELDMANN M; BRENNAN FM; CHANTRY D; HAWORTH C; TURNER M; KATSIKIS P; LONDEI M; ABNEY E; et alBUCHAN G; BARRETT K; CORCORAN A; KISSONERGHIS M; ZHENG R; GRUBECKLOEBENSTEIN B; BARKLEY D; CHU CQ; FIELD M; MAINI RN. (Feb 1991). CYTOKINE ASSAYS - ROLE IN EVALUATION OF THE PATHOGENESIS OF AUTOIMMUNITY. IMMUNOL REV. 119:105-123.
Zheng RQ; Abney E; Chu CQ; Field M; Grubeck-Loebenstein B; Maini RN; Feldmann M. (Feb 1991). Detection of interleukin-6 and interleukin-1 production in human thyroid epithelial cells by non-radioactive in situ hybridization and immunohistochemical methods. Clin Exp Immunol. 83:314-319.
Brennan FM; Field M; Chu CQ; Feldmann M; Maini RN. (1991). Cytokine expression in rheumatoid arthritis. Br J Rheumatol. 30 Suppl 1:76-80.
Feldmann M. (Jan 1991). Cytokine networks: do we understand them well enough to facilitate clinical benefits?. Eur Cytokine Netw. 2:5-9.
Howells G; Pham P; Taylor D; Foxwell B; Feldmann M. (Jan 1991). Interleukin 4 induces interleukin 6 production by endothelial cells: synergy with interferon-gamma. Eur J Immunol. 21:97-101. DOI.
Field M; Chu C; Feldmann M; Maini RN. (1991). Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int. 11:45-50.
Zheng RQ; Abney ER; Grubeck-Loebenstein B; Dayan C; Maini RN; Feldmann M. (Dec 1990). Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. J Autoimmun. 3:727-736.
Grubeck-Loebenstein B; Turner M; Pirich K; Kassal H; Londei M; Waldhäusl W; Feldmann M. (Nov 1990). CD4+ T-cell clones from autoimmune thyroid tissue cannot be classified according to their lymphokine production. Scand J Immunol. 32:433-440.
Gray PW; Barrett K; Chantry D; Turner M; Feldmann M. (Oct 1990). Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A. 87:7380-7384.
Brennan FM; Zachariae CO; Chantry D; Larsen CG; Turner M; Maini RN; Matsushima K; Feldmann M. (Sep 1990). Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol. 20:2141-2144. DOI.
Brennan FM; Chantry D; Turner M; Foxwell B; Maini R; Feldmann M. (Aug 1990). Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol. 81:278-285.
NAOR D; ESSERY G; TARCIC N; KAHAN M; LAMB JR; FELDMANN M. (Aug 1990). SPECIFIC INTERACTIONS BETWEEN A HUMAN CD4+ CLONE AND AUTOLOGOUS CD4+ BIFUNCTIONAL IMMUNOREGULATORY CLONES. IMMUNOL REV. 116:63-83.
Maini RN; Plater-Zyberk C; Brown CM; Aghamohammadi S; Brennan FM; Feldmann M. (Jul 1990). CD5+B cells in rheumatoid arthritis and Sjögren's syndrome. Clin Exp Rheumatol. 8 Suppl 5:67-68.
Naor D; Essery G; Tarcic N; Kahan M; Feldmann M. (Jul 1990). Interactions between autologous T cell clones. Cell Immunol. 128:490-502.
FELDMANN M; BRENNAN FM; CHANTRY D; HAWORTH C; TURNER M; ABNEY E; BUCHAN G; BARRETT K; et alBARKLEY D; CHU A; FIELD M; MAINI RN. (Jun 1990). CYTOKINE PRODUCTION IN THE RHEUMATOID JOINT - IMPLICATIONS FOR TREATMENT. ANN RHEUM DIS. 480-486.
Feldmann M; Brennan FM; Chantry D; Haworth C; Turner M; Abney E; Buchan G; Barrett K; et alBarkley D; Chu A. (Jun 1990). Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis. 49 Suppl 1:480-486.
FELDMANN M. (Jun 1990). HEBERDEN PAPERS - MOLECULAR-BIOLOGY APPROACHES IN RHEUMATOLOGY RESEARCH - FOREWORD. ANN RHEUM DIS. 425-425.
Turner M; Chantry D; Feldmann M. (May 1990). Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine. 2:211-216.
Barkley DE; Feldmann M; Maini RN. (Apr 1990). Cells with dendritic morphology and bright interleukin-1 alpha staining circulate in the blood of patients with rheumatoid arthritis. Clin Exp Immunol. 80:25-31.
Londei M; Verhoef A; Hawrylowicz C; Groves J; De Berardinis P; Feldmann M. (Feb 1990). Interleukin 7 is a growth factor for mature human T cells. Eur J Immunol. 20:425-428. DOI.
TODD I; HAMMOND LJ; JAMES RFL; FELDMANN M; BOTTAZZO GF. (Jan 1990). EPIDERMAL GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-ALPHA SUPPRESS HLA CLASS-II INDUCTION IN HUMAN THYROID EPITHELIAL-CELLS. IMMUNOLOGY. 69:91-96.
Chantry D; Turner M; Brennan F; Kingsbury A; Feldmann M. (Jan 1990). Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine. 2:60-67.
Varma C; Chantry D; Brennan F; Turner M; Katz F; Feldmann M. (Jan 1990). Interleukin 7 and interleukin 4 stimulate human thymocyte growth through distinct mechanisms. Cytokine. 2:55-59.
Turner M; Chantry D; Buchan G; Barrett K; Feldmann M. (1 Dec 1989). Regulation of expression of human IL-1 alpha and IL-1 beta genes. J Immunol. 143:3556-3561.
Londei M; Verhoef A; De Berardinis P; Kissonerghis M; Grubeck-Loebenstein B; Feldmann M. (Nov 1989). Definition of a population of CD4-8- T cells that express the alpha beta T-cell receptor and respond to interleukins 2, 3, and 4. Proc Natl Acad Sci U S A. 86:8502-8506.
LONDEI M; VERHOEF A; DEBERARDINIS P; KISSONERGHIS M; GRUBECKLOEBENSTEIN B; FELDMANN M. (Nov 1989). DEFINITION OF A POPULATION OF CD4-8-T CELLS THAT EXPRESS THE ALPHA-BETA-T-CELL RECEPTOR AND RESPOND TO INTERLEUKIN-2, INTERLEUKIN-3, AND INTERLEUKIN-4. P NATL ACAD SCI USA. 86:8502-8506.
Partridge M; Green MR; Langdon JD; Feldmann M. (Oct 1989). Production of TGF-alpha and TGF-beta by cultured keratinocytes, skin and oral squamous cell carcinomas--potential autocrine regulation of normal and malignant epithelial cell proliferation. Br J Cancer. 60:542-548.
Grubeck-Loebenstein B; Buchan G; Chantry D; Kassal H; Londei M; Pirich K; Barrett K; Turner M; et alWaldhausl W; Feldmann M. (Sep 1989). Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol. 77:324-330.
Brennan F; Plater-Zyberk C; Maini RN; Feldmann M. (Aug 1989). Coordinate expansion of 'fetal type' lymphocytes (TCR gamma delta+T and CD5+B) in rheumatoid arthritis and primary Sjögren's syndrome. Clin Exp Immunol. 77:175-178.
Barkley D; Allard S; Feldmann M; Maini RN. (Aug 1989). Increased expression of HLA-DQ antigens by interstitial cells and endothelium in the synovial membrane of rheumatoid arthritis patients compared with reactive arthritis patients. Arthritis Rheum. 32:955-963.
Brennan FM; Chantry D; Jackson A; Maini R; Feldmann M. (29 Jul 1989). Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:244-247.
Hewitt CR; Feldmann M. (15 Jul 1989). Human T cell clones present antigen. J Immunol. 143:762-769.
Barkley D; Feldmann M; Maini RN. (21 Jun 1989). The detection by immunofluorescence of distinct cell populations producing interleukin-1 alpha and interleukin-1 beta in activated human peripheral blood. J Immunol Methods. 120:277-283.
Chantry D; Turner M; Abney E; Feldmann M. (15 Jun 1989). Modulation of cytokine production by transforming growth factor-beta. J Immunol. 142:4295-4300.
Brennan FM; Chantry D; Jackson AM; Maini RN; Feldmann M. (Jun 1989). Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun. 2 Suppl:177-186.
BRENNAN FM; CHANTRY D; JACKSON AM; MAINI RN; FELDMANN M. (Jun 1989). CYTOKINE PRODUCTION IN CULTURE BY CELLS ISOLATED FROM THE SYNOVIAL-MEMBRANE. J AUTOIMMUN. 2:177-186.
Plater-Zyberk C; Brennan FM; Feldmann M; Maini RN. (Jun 1989). 'Fetal-type' B and T lymphocytes in rheumatoid arthritis and primary Sjögren's syndrome. J Autoimmun. 2 Suppl:233-241.
PLATERZYBERK C; BRENNAN FM; FELDMANN M; MAINI RN. (Jun 1989). FETAL-TYPE LYMPHOCYTE-B AND LYMPHOCYTE-T IN RHEUMATOID-ARTHRITIS AND PRIMARY SJOGRENS SYNDROME. J AUTOIMMUN. 2:233-241.
Grubeck-Loebenstein B; Buchan G; Chantry D; Turner M; Londei M; Feldmann M. (Jun 1989). Intrathyroidal cytokine production in thyroid disease. J Autoimmun. 2 Suppl:171-176.
GRUBECKLOEBENSTEIN B; BUCHAN G; CHANTRY D; TURNER M; LONDEI M; FELDMANN M. (Jun 1989). INTRATHYROIDAL CYTOKINE PRODUCTION IN THYROID-DISEASE. J AUTOIMMUN. 2:171-176.
NAOR D; ESSERY G; KAHAN M; FELDMANN M. (Jun 1989). T-CELL CLONE ANTI-CLONE INTERACTIONS - EFFECTS ON SUPPRESSOR AND HELPER ACTIVITIES. J AUTOIMMUN. 2:3-14.
Naor D; Essery G; Kahan M; Feldmann M. (Jun 1989). T-cell clone anti-clone interactions. Effects on suppressor and helper activities. J Autoimmun. 2 Suppl:3-14.
ASHWORTH J; TURNER M; HITCH G; FELDMANN M; BREATHNACH SM. (Apr 1989). EPIDERMAL CYTOKINE MESSENGER-RNA EXPRESSION IN LESIONAL AND UNINVOLVED SKIN IN PSORIASIS-VULGARIS. CLIN RES. 37:A688-A688.
Chantry D; Turner M; Feldmann M. (Apr 1989). Interleukin 7 (murine pre-B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta. Eur J Immunol. 19:783-786. DOI.
FELDMANN M; LONDEI M; HAWORTH C. (Apr 1989). T-CELLS AND LYMPHOKINES. BRIT MED BULL. 45:361-370.
ASHWORTH J; TURNER M; HITCH G; FELDMANN M; BREATHNACH SM. (Mar 1989). EPIDERMAL CYTOKINE MESSENGER-RNA EXPRESSION IN LESIONAL AND UNINVOLVED SKIN IN PSORIASIS-VULGARIS. J INVEST DERMATOL. 92:397-397.
CALDER V; OWEN S; WATSON C; FELDMANN M; DAVISON A. (Mar 1989). MS - A LOCALIZED IMMUNE DISEASE OF THE CENTRAL NERVOUS-SYSTEM. IMMUNOL TODAY. 10:99-103.
GRUBECKLOEBENSTEIN B; BUCHAN G; SADEGHI R; KISSONERGHIS M; LONDEI M; TURNER M; PIRICH K; ROKA R; et alNIEDERLE B; KASSAL H; WALDHAUSL W; FELDMANN M. (Mar 1989). TRANSFORMING GROWTH FACTOR-BETA REGULATES THYROID GROWTH - ROLE IN THE PATHOGENESIS OF NONTOXIC GOITER. J CLIN INVEST. 83:764-770.
DEBERARDINIS P; LONDEI M; JAMES RFL; LAKE SP; WISE PH; FELDMANN M. (11 Feb 1989). CD4+ T-CELL DAMAGE TO ISLET BETA-CELLS. LANCET. 1:329-329.
LIPOLDOVA M; LONDEI M; GRUBECKLOEBENSTEIN B; FELDMANN M; OWEN MJ. (Feb 1989). ANALYSIS OF T-CELL RECEPTOR USAGE IN ACTIVATED T-CELL CLONES FROM HASHIMOTOS THYROIDITIS AND GRAVES-DISEASE. J AUTOIMMUN. 2:1-13.
Portillo G; Turner M; Chantry D; Feldmann M. (Feb 1989). Effect of cytokines on HLA-DR and IL-1 production by a monocytic tumour, THP-1. Immunology. 66:170-175.
FELDMANN M. (1989). MOLECULAR MECHANISMS INVOLVED IN HUMAN AUTOIMMUNE-DISEASES - RELEVANCE OF CHRONIC ANTIGEN PRESENTATION - CLASS-II EXPRESSION AND CYTOKINE PRODUCTION. IMMUNOLOGY. 66-73.
NAOR D; ESSERY G; TARCIC N; DEBERARDINIS P; KAHAN M; FELDMANN M. (Jan 1989). AUTOREACTIVITY AGAINST CLASS-I OR CLASS-II ANTIGENS - IMMUNOLOGICAL DOWN-REGULATION MECHANISM. B I PASTEUR. 87:3-17.
TAYLOR DJ; FELDMANN M; EVANSON JM; WOOLLEY DE. (1989). COMPARATIVE AND COMBINED EFFECTS OF TRANSFORMING GROWTH FACTOR-ALPHA AND FACTOR-BETA, INTERLEUKIN-1 AND INTERFERON-GAMMA ON RHEUMATOID SYNOVIAL CELL-PROLIFERATION, GLYCOLYSIS AND PROSTAGLANDIN-E PRODUCTION. RHEUMATOL INT. 9:65-70.
Kissonerghis AM; Maini RN; Feldmann M. (Jan 1989). High rate of HLA class II mRNA synthesis in rheumatoid arthritis joints and its persistence in culture: down-regulation by recombinant interleukin 2. Scand J Immunol. 29:73-82.
Chantry D; Winearls CG; Maini RN; Feldmann M. (Jan 1989). Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol. 19:189-192. DOI.
Feldmann M. (1989). Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation. Class II expression and cytokine production. Immunol Suppl. 2:66-71.
Londei M; Savill CM; Verhoef A; Brennan F; Leech ZA; Duance V; Maini RN; Feldmann M. (Jan 1989). Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A. 86:636-640.
Chantry D; Feldmann M. (1989). The role of cytokines in autoimmunity. Biotechnol Ther. 1:361-409.
Grubeck-Loebenstein B; Buchan G; Sadeghi R; Kissonerghis M; Londei M; Turner M; Pirich K; Roka R; et alNiederle B; Kassal H; Waldhausl W; Feldmann M. (1989). Transforming growth factor beta regualtes thyroid growth: role in the pathogenesis of non toxic goiter. Journal of Clinical Investigation. 83:764-770.
Kissonerghis AM; Grubeck-Loebenstein B; Pirich K; Feldmann M; Londei M. (1989). Tumour necrosis factor synergises with gamma interferon on the induction of mRNA for DR alpha chain on thyrocytes from Graves' disease and non toxic goitre. Autoimmunity. 4:255-266.
Turner M; Chantry D; Feldmann M. (31 Oct 1988). Post-transcriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1. Biochem Biophys Res Commun. 156:830-839.
de Berardinis P; Londei M; James RF; Lake SP; Wise PH; Feldmann M. (8 Oct 1988). Do CD4-positive cytotoxic T cells damage islet beta cells in type 1 diabetes?. Lancet. 2:823-824.
BARKLEY D; BROWN C; PLATERZYBERK C; FELDMANN M; MAINI RN. (Oct 1988). CELLS CONTAINING IL-1-ALPHA CIRCULATE IN THE BLOOD OF PATIENTS. SCAND J IMMUNOL. 28:503-503.
HARTWIG U; VENKITARAMAN A; IKEDA H; TROWSDALE J; FELDMANN M. (Oct 1988). EFFECT OF LYMPHOKINES ON MHC CLASS-II GENE-EXPRESSION IN A MURINE B-CELL TRANSFECTANT CARRYING A DR GENE CONSTRUCT. IMMUNOBIOLOGY. 178:122-123.
FORRE O; WAALEN K; NATVIG JB; FELDMANN M. (Oct 1988). EVIDENCE FOR THE ACTIVATION OF SYNOVIAL T-CELLS. SCAND J IMMUNOL. 28:496-496.
BARKLEY D; ALLARD S; FELDMANN M; MAINI RN. (Oct 1988). IMPORTANCE OF DIFFERENTIAL CLASS-II EXPRESSION AND DENDRITIC CELLS IN THE DISEASE CHRONICITY OF RHEUMATOID-ARTHRITIS - AN IMMUNOHISTOLOGICAL STUDY. SCAND J IMMUNOL. 28:503-503.
Howells GL; Chantry D; Feldmann M. (Oct 1988). Interleukin 1 (IL-1) and tumour necrosis factor synergise in the induction of IL-1 synthesis by human vascular endothelial cells. Immunol Lett. 19:169-173.
HOWELLS GL; CHANTRY D; FELDMANN M. (Oct 1988). INTERLEUKIN-1 (IL-1) AND TUMOR NECROSIS FACTOR SYNERGIZE IN THE INDUCTION OF IL-1 SYNTHESIS BY HUMAN VASCULAR ENDOTHELIAL-CELLS. IMMUNOL LETT. 19:169-174.
FIELD M; TURNER M; FELDMANN M; MAINI RN. (Oct 1988). INTERLEUKIN-6 IN RHEUMATOID JOINTS. SCAND J IMMUNOL. 28:504-504.
FELDMANN M; KISSONERGHIS M; BRENNAN F; MAIN RN. (Oct 1988). ROLE OF SYNOVIAL HLA CLASS-II EXPRESSION IN RHEUMATOID-ARTHRITIS. SCAND J IMMUNOL. 28:496-496.
Brennan FM; Allard S; Londei M; Savill C; Boylston A; Carrel S; Maini RN; Feldmann M. (Sep 1988). Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis. Clin Exp Immunol. 73:417-423.
Buchan G; Barrett K; Turner M; Chantry D; Maini RN; Feldmann M. (Sep 1988). Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol. 73:449-455.
Brennan FM; Londei M; Jackson AM; Hercend T; Brenner MB; Maini RN; Feldmann M. (Aug 1988). T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun. 1:319-326.
De Berardinis P; Londei M; Kahan M; Balsano F; Kontiainen S; Gale EA; Bottazzo GF; Feldmann M. (Aug 1988). The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+. Clin Exp Immunol. 73:255-259.
Essery G; Feldmann M; Lamb JR. (Jul 1988). Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology. 64:413-417.
De Berardinis P; Londei M; Carrel S; Feldmann M. (Jul 1988). Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis. Immunology. 64:439-443.
Turner M; Feldmann M. (30 Jun 1988). Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA. Biochem Biophys Res Commun. 153:1144-1151.
Grubeck-Loebenstein B; Londei M; Greenall C; Pirich K; Kassal H; Waldhäusl W; Feldmann M. (May 1988). Pathogenetic relevance of HLA class II expressing thyroid follicular cells in nontoxic Goiter and in Graves' disease. J Clin Invest. 81:1608-1614. DOI.
FELDMANN M. (May 1988). T-CELL ACTIVATION IN HEALTH AND DISEASE. IMMUNOL TODAY. 9:121-124.
FLOREANI A; BASSENDINE MF; FELDMANN M; MICHISON H; JAMES OFW; BENNETT MK. (Apr 1988). TISSUE EXPRESSION OF HLA CLASS-II ANTIGENS AND LYMPHOCYTE SUBPOPULATIONS IN PRIMARY BILIARY-CIRRHOSIS (PBC). ITAL J GASTROENTEROL. 20:99-100.
Feldmann M; Londei M; Grubeck-Loebenstein B; De Berardinis P; Leech Z; Turner M; Barrett K; Buchan G; et alMaini RN. (Apr 1988). Understanding what infiltrating cells do in autoimmunity: combination of cellular and molecular approaches. Transplant Proc. 20:311-314.
TAYLOR DJ; WHITEHEAD RJ; EVANSON JM; WESTMACOTT D; FELDMANN M; BERTFIELD H; MORRIS MA; WOOLLEY DE. (15 Feb 1988). EFFECT OF RECOMBINANT CYTOKINES ON GLYCOLYSIS AND FRUCTOSE 2,6-BISPHOSPHATE IN RHEUMATOID SYNOVIAL-CELLS INVITRO. BIOCHEM J. 250:111-115.
Buchan G; Barrett K; Fujita T; Taniguchi T; Maini R; Feldmann M. (Feb 1988). Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol. 71:295-301.
FELDMANN M; BARRETT K; BUCHAN G; TURNER M; BRENNAN F; CHANTRY D. (1988). ANALYSIS OF CYTOKINE GENE-EXPRESSION IN RHEUMATOID-ARTHRITIS. LYMPHOKINE RES. 7:333-333.
Feldmann M; Londei M; Leech Z; Brennan F; Savill C; Maini RN. (1988). Analysis of T cell clones in rheumatoid arthritis. Springer Semin Immunopathol. 10:157-167.
HAWORTH C; HOWELLS G; CHANTRY D; FELDMANN M. (1988). AUTOCRINE AND PARACRINE MECHANISMS OF CYTOKINE PRODUCTION BY HUMAN VASCULAR ENDOTHELIAL-CELLS. LYMPHOKINE RES. 7:289-289.
VYAKARNAM A; TURNER M; MCKEATING J; FELDMANN M; BEVERLEY PCL. (1988). CYTOKINE GENE-EXPRESSION IN HIV INFECTED-CELLS. LYMPHOKINE RES. 7:338-338.
Londei M; Grubeck-Loebenstein B; de Berardinis P; Greenall C; Feldmann M. (Jan 1988). Efficient propagation and cloning of human T cells in the absence of antigen by means of OKT3, interleukin 2, and antigen-presenting cells. Scand J Immunol. 27:35-46.
Hirano T; Matsuda T; Turner M; Miyasaka N; Buchan G; Tang B; Sato K; Shimizu M; et alMaini R; Feldmann M; Kishimoto T. (1988). Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology. 18:1797-1801.
TURNER M; CHANTRY D; BARRETT K; FELDMANN M. (1988). EXPRESSION OF HUMAN INTERLEUKIN-1-ALPHA AND BETA-GENES IN NORMAL BLOOD MONONUCLEAR-CELLS AND CELL-LINES. LYMPHOKINE RES. 7:263-263.
WAGNER L; TURNER M; LONDEI M; FELDMANN M; GRUBECKLOEBENSTEIN B. (1988). INTRATHYROIDAL T-CELLS CANNOT BE CLASSIFIED ACCORDING TO THEIR LYMPHOKINE PRODUCTION. ANN ENDOCRINOL-PARIS. 49:206-206.
Feldmann M; Londei M; Kissonerghis M; Portillo G; Leech Z; Ziegler A; Grubeck-Loebenstein B. (1988). Regulation of HLA class II expression and the pathogenesis of autoimmunity. Concepts Immunopathol. 5:44-56.
CHANTRY D; TURNER M; FELDMANN M. (1988). REGULATION OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR MESSENGER-RNA AND PROTEIN BY TRANSFORMING GROWTH FACTOR-BETA. LYMPHOKINE RES. 7:283-283.
Feldmann M; Kissonerghis AM; Buchan G; Brennan F; Turner M; Haworth C; Barrett K; Chantry D; et alZiegler A; Maini RN. (1988). Role of HLA class II and cytokine expression in rheumatoid arthritis. Scand J Rheumatol Suppl. 76:39-46.
BRENNAN FM; CHANTRY D; JACKSON A; MAINI R; FELDMANN M. (1988). SUPPRESSION OF IL1 BIOACTIVITY IN SYNOVIAL CELL-CULTURES BY POLYCLONAL ANTI-TNF ANTIBODY. LYMPHOKINE RES. 7:333-333.
GRUBECKLOEBENSTEIN B; PIRICH K; WALDHAUSL W; LONDEI M; FELDMANN M. (1988). TRANSFORMING GROWTH FACTOR-BETA ACTS AS AN AUTOCRINE GROWTH-REGULATOR IN THE THYROID-GLAND AND MAY BE IMPORTANT IN THE PATHOGENESIS OF NONTOXIC GOITER. ANN ENDOCRINOL-PARIS. 49:201-201.
CALDER VL; BELLAMY AS; OWEN S; LEWIS C; RUDGE P; DAVISON AN; FELDMANN M. (Dec 1987). EFFECTS OF CYCLOSPORINE-A ON EXPRESSION OF IL-2 AND IL-2 RECEPTORS IN NORMAL AND MULTIPLE-SCLEROSIS PATIENTS. CLIN EXP IMMUNOL. 70:570-577.
Turner M; Londei M; Feldmann M. (Dec 1987). Human T cells from autoimmune and normal individuals can produce tumor necrosis factor. Eur J Immunol. 17:1807-1814. DOI.
Lamb JR; Zanders ED; Sewell W; Crumpton MJ; Feldmann M; Owen MJ. (Nov 1987). Antigen-specific T cell unresponsiveness in cloned helper T cells mediated via the CD2 or CD3/Ti receptor pathways. Eur J Immunol. 17:1641-1644. DOI.
Venkitaraman AR; Culbert EJ; Feldmann M. (Oct 1987). A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma. Eur J Immunol. 17:1441-1446. DOI.
HIRANO T; MATSUDA T; TURNER M; FELDMANN M; TANG B; MIYASAKA N; SHIMIZU M; KISHIMOTO T. (Sep 1987). B-CELL STIMULATORY FACTOR-II (BSF2/IL-6) AND RHEUMATOID-ARTHRITIS. P JPN ACAD B-PHYS. 63:281-283.
TODD I; PUJOLBORRELL R; HAMMOND LJ; MCNALLY JM; FELDMANN M; BOTTAZZO GF. (Sep 1987). ENHANCEMENT OF THYROCYTE HLA CLASS-II EXPRESSION BY THYROID STIMULATING HORMONE. CLIN EXP IMMUNOL. 69:524-531.
TODD I; PUJOLBORRELL R; ABDULKARIM BAS; HAMMOND LJ; FELDMANN M; BOTTAZZO GF. (Sep 1987). HLA-D SUBREGION EXPRESSION BY THYROID EPITHELIUM IN AUTOIMMUNE THYROID-DISEASES AND INDUCED INVITRO. CLIN EXP IMMUNOL. 69:532-542.
TURNER MJC; LONDEI M; FELDMANN M. (Aug 1987). POSSIBLE ROLE FOR TNF IN THE PATHOGENESIS OF AUTOIMMUNE-DISEASES. IMMUNOBIOLOGY. 175:105-105.
PUJOLBORRELL R; TODD I; LONDEI M; FELDMANN M; BOTTAZZO GF. (May 1987). NEW IDEAS IN THYROID AUTOIMMUNITY. HORM RES. 26:118-124.
PUJOLBORRELL R; TODD I; DOSHI M; BOTTAZZO GF; SUTTON R; GRAY D; ADOLF GR; FELDMANN M. (19 Mar 1987). HLA CLASS-II INDUCTION IN HUMAN ISLET CELLS BY INTERFERON-GAMMA PLUS TUMOR-NECROSIS-FACTOR OR LYMPHOTOXIN. NATURE. 326:304-306.
LONDEI M; LIPODOWA M; GRUBECKLOEBENSTEIN B; TURNER M; OWEN M; FELDMANN M. (1987). ANALYSIS OF LYMPHOKINE PRODUCTION AND CLONALITY OF T-CELL CLONES FROM HASHIMOTOS DISEASE. ANN ENDOCRINOL-PARIS. 48:147-147.
Cantrell D; Davies AA; Londei M; Feldmann M; Crumpton MJ. (1987). Association of phosphorylation of the T3 antigen with immune activation of T lymphocytes. Nature. 325:540-542.
LONDEI M; GRUBECKLOEBENSTEIN B; GREENALL C; TURNER M; FELDMANN M. (1987). COMPARISON OF THE CELLULAR INFILTRATE OF HASHIMOTOS-THYROIDITIS INVIVO AND AFTER INVITRO-CELL GROWTH. ACTA ENDOCRINOL-COP. 115:86-88.
GRUBECKLOEBENSTEIN B; BUCHAN G; LONDEI M; TURNER M; PIRICH K; WALDHAUSL W; FELDMANN M. (1987). CYTOKINE MESSENGER-RNA PRODUCTION AND AUTOANTIGEN RECOGNITION IN GRAVES-DISEASE (GD) AND NON TOXIC GOITER (NTG). ANN ENDOCRINOL-PARIS. 48:107-107.
Pujol-Borrell R; Todd I; Doshi M; Bottazzo GF; Sutton R; Gray D; Adolf GR; Feldmann M. (1987). HAL class II induction in human islet cells by interferon-gamma plus tumour necrosis factor of lymphotoxin. Nature. 326:304-306.
Feldmann M; Londei M; Buchan G. (1987). Interferons and autoimmunity. Interferon. 9:75-90.
Feldmann M. (1987). Regulation of HLA class II expression and its role in autoimmune disease. Ciba Found Symp. 129:88-108.
LONDEI M; GRUBECKLOEBENSTEIN B; KISSONERGHIS M; AUSTIN P; TROWSDALE J; GREENALL C; FELDMANN M. (1987). THYROCYTES CAN SYNTHESIZE HLA CLASS-II MOLECULES. ACTA ENDOCRINOL-COP. 115:82-85.
FELDMANN M; LONDEI M; DEBERARDINIS P; ESSERY G; GREENALL C; GRUBECKLOEBENSTEIN B; KNIGHT J; LEECH Z; et alKINGSBURY A; MAINI RN. (Dec 1986). AUTOIMMUNE DISORDERS - ANALYSIS BY STUDY OF T-CELLS, IMPLICATIONS AND SPECULATIONS. AGENTS ACTIONS. 19:252-255.
CHAIN BM; LONDEI M; FELDMANN M. (Sep 1986). BIOCHEMICAL AND CELLULAR QUESTIONS IN ANTIGEN PROCESSING. ANN INST PASTEUR IMM. D137:320-323.
BELLAMY A; DAVISON AN; FELDMANN M. (Aug 1986). DERIVATION OF GANGLIOSIDE-SPECIFIC T-CELL LINES OF SUPPRESSOR OR HELPER PHENOTYPE FROM CEREBROSPINAL-FLUID OF MULTIPLE-SCLEROSIS PATIENTS. J NEUROIMMUNOL. 12:107-120.
PUJOLBORRELL R; TODD I; DOSHI M; SUTTON R; GRAY D; FELDMANN M; BOTTAZZO GF. (Aug 1986). INVITRO INDUCTION OF HLA CLASS-II EXPRESSION IN HUMAN B-CELLS - REQUIREMENT FOR A 2 MEDIATOR SIGNAL. DIABETOLOGIA. 29:A585-A585.
DEBERARDINIS P; LONDEI M; GALE E; BOTTAZZO GF; FELDMANN M. (Aug 1986). T-CELL LINE RESPONDING TO INSULIN IN TYPE-1 (INSULIN-DEPENDENT) DIABETES. DIABETOLOGIA. 29:A532-A532.
TODD I; LONDEI M; PUJOLBORRELL R; MIRAKIAN R; FELDMANN M; BOTTAZZO GF. (30 Jul 1986). HLA-D/DR EXPRESSION ON EPITHELIAL-CELLS - THE FINGER ON THE TRIGGER. ANN NY ACAD SCI. 475:241-250.
TODD I; PUJOLBORRELL R; BOTTAZZO GF; LONDEI M; FELDMANN M. (Jul 1986). AUTOANTIGEN PRESENTATION BY TARGET-CELLS - ITS POSSIBLE ROLE IN DETERMINING AUTOANTIBODY SPECIFICITY. ANN INST PASTEUR IMM. D137:168-173.
PUJOLBORRELL R; TODD I; DOSHI M; GRAY D; FELDMANN M; BOTTAZZO GF. (Jul 1986). DIFFERENTIAL EXPRESSION AND REGULATION OF MHC PRODUCTS IN THE ENDOCRINE AND EXOCRINE CELLS OF THE HUMAN-PANCREAS. CLIN EXP IMMUNOL. 65:128-139.
WOODROOFE MN; BELLAMY AS; FELDMANN M; DAVISON AN; CUZNER ML. (Jul 1986). IMMUNOCYTOCHEMICAL CHARACTERIZATION OF THE IMMUNE-REACTION IN THE CENTRAL-NERVOUS-SYSTEM IN MULTIPLE-SCLEROSIS - POSSIBLE ROLE FOR MICROGLIA IN LESION GROWTH. J NEUROL SCI. 74:135-152.
FELDMANN M; LONDEI M; ESSERY G. (Jun 1986). AUTOIMMUNE-DISEASE - SYNERGY OF HLA CLASS-II OVEREXPRESSION AND ABROGATION OF SELF TOLERANCE. PATHOL BIOL. 34:779-782.
CHAIN BM; KAY PM; FELDMANN M. (Jun 1986). THE CELLULAR PATHWAY OF ANTIGEN PRESENTATION - BIOCHEMICAL AND FUNCTIONAL-ANALYSIS OF ANTIGEN PROCESSING IN DENDRITIC CELLS AND MACROPHAGES. IMMUNOLOGY. 58:271-276.
FELDMANN M. (May 1986). CELLS THAT SUPPRESS IMMUNITY. RECHERCHE. 17:692-699.
KAYE PM; FELDMANN M. (Apr 1986). REGULATION OF MACROPHAGE ACCESSORY CELL-ACTIVITY BY MYCOBACTERIA .1. IA EXPRESSION IN NORMAL AND IRRADIATED MICE INFECTED WITH MYCOBACTERIUM-MICROTI. CLIN EXP IMMUNOL. 64:20-27.
KAYE PM; SIMS M; FELDMANN M. (Apr 1986). REGULATION OF MACROPHAGE ACCESSORY CELL-ACTIVITY BY MYCOBACTERIA .2. INVITRO INHIBITION OF IA EXPRESSION BY MYCOBACTERIUM-MICROTI. CLIN EXP IMMUNOL. 64:28-34.
LAMB JR; FELDMANN M; GREEN N; LERNER RA. (Mar 1986). INFLUENCE OF ANTIGEN STRUCTURE ON THE ACTIVATION AND INDUCTION OF UNRESPONSIVENESS IN CLONED HUMAN LYMPHOCYTES-T. IMMUNOLOGY. 57:331-335.
LEECH ZA; FELDMANN M; MAINI RN. (1986). INTERLEUKIN-2 (IL-2) DEPENDENT T-CELL CLONES FROM SYNOVIAL-FLUID OF A PATIENT WITH RHEUMATOID-ARTHRITIS (RA). BRIT J RHEUMATOL. 25:87-87.
BUCHAN G; BARRETT K; TURNER M; MAINI RN; FELDMANN M. (1986). PRODUCTION OF IMMUNOREGULATORY MESSENGER-RNA SPECIES WITHIN THE RHEUMATOID JOINT. BRIT J RHEUMATOL. 25:113-113.
TURNER M; BUCHAN G; BARRETT K; FELDMANN M. (1986). TUMOR-NECROSIS-FACTOR INDUCTION OF IL-1. BRIT J RHEUMATOL. 25:110-110.
TODD I; PUJOLBORRELL R; BOTTAZZO GF; FELDMANN M. (Jan 1986). EPITHELIAL MHC CLASS-II SUBREGION EXPRESSION IN AUTOIMMUNITY. IMMUNOL TODAY. 7:6-6.
FELDMANN M; LAMB JR; LONDEI M. (1986). HUMAN T-CELL CLONES, TOLERANCE, AND THE ANALYSIS OF AUTOIMMUNITY. CURR TOP MICROBIOL. 126:207-211.
JAMES RFL; SUNSHINE GH; EDWARDS S; MAUDSLEY DJ; FELDMANN M. (1985). AUGMENTATION OF CELL-MEDIATED RESPONSES INVITRO BY A MONOCLONAL ANTI-HELPER FACTOR ANTIBODY. IMMUNOLOGY. 54:693-700.
ZANDERS ED; FELDMANN M; LAMB JR. (1985). BIOCHEMICAL EVENTS INITIATED BY EXPOSURE OF HUMAN LYMPHOCYTE-T CLONES TO IMMUNOGENIC AND TOLEROGENIC CONCENTRATIONS OF ANTIGEN. EUR J IMMUNOL. 15:302-305.
AUSTIN P; TROWSDALE J; RUDD C; BODMER W; FELDMANN M; LAMB J. (1985). FUNCTIONAL EXPRESSION OF HLA-DP GENES TRANSFECTED INTO MOUSE FIBROBLASTS. NATURE. 313:61-64.
LONDEI M; BOTTAZZO GF; FELDMANN M. (1985). HUMAN T-CELL CLONES FROM AUTOIMMUNE THYROID-GLANDS - SPECIFIC RECOGNITION OF AUTOLOGOUS THYROID-CELLS. SCIENCE. 228:85-89.
TODD I; PUJOLBORRELL R; HAMMOND LJ; BOTTAZZO GF; FELDMANN M. (1985). INTERFERON-GAMMA INDUCES HLA-DR EXPRESSION BY THYROID EPITHELIUM. CLIN EXP IMMUNOL. 61:265-273.
KAYE PM; CHAIN BM; FELDMANN M. (1985). NONPHAGOCYTIC DENDRITIC CELLS ARE EFFECTIVE ACCESSORY CELLS FOR ANTI-MYCOBACTERIAL RESPONSES INVITRO. J IMMUNOL. 134:1930-1934.
FELDMANN M; ESSERY G; LONDEI M; AUSTIN P; TROWSDALE J; BODMER W; LAMB JR. (1985). ROLE OF IL-1 IN THE ACTIVATION AND INACTIVATION OF HUMAN T-CELL CLONES - RELEVANCE TO RHEUMATOLOGICAL DISEASE. BRIT J RHEUMATOL. 24:102-104.
BELLAMY AS; CALDER VL; FELDMANN M; DAVISON AN. (1985). THE DISTRIBUTION OF INTERLEUKIN-2 RECEPTOR BEARING LYMPHOCYTES IN MULTIPLE-SCLEROSIS - EVIDENCE FOR A KEY ROLE OF ACTIVATED LYMPHOCYTES. CLIN EXP IMMUNOL. 61:248-256.
FELDMANN M; ZANDERS ED; LAMB JR. (1985). TOLERANCE IN T-CELL CLONES. IMMUNOL TODAY. 6:58-62.
KAYE PM; CHAIN BM; FELDMANN M. (1984). ACCESSORY CELL HETEROGENEITY IN ANTI-MYCOBACTERIAL RESPONSES. IMMUNOBIOLOGY. 167:155-156.
CULBERT EJ; KONTIAINEN S; FELDMANN M. (1984). ANTISERA TO ANTIGEN-SPECIFIC HELPER AND SUPPRESSOR FACTORS DEFINE FUNCTION-RELATED ISOTYPIC T-CELL SURFACE DETERMINANTS. IMMUNOBIOLOGY. 167:138-139.
CULBERT EJ; KONTIAINEN S; JAMES RFL; FELDMANN M. (1984). CLONED T-CELLS EXPRESS CELL-SURFACE DETERMINANTS SHARED WITH THEIR SECRETED ANTIGEN-SPECIFIC FACTORS. IMMUNOBIOLOGY. 167:139-139.
ZANDERS ED; FELDMANN M; GREEN N; LAMB JR. (1984). DIRECT EVALUATION OF ANTIGEN-BINDING TO HUMAN LYMPHOCYTE-T CLONES - INVOLVEMENT OF MAJOR HISTOCOMPATIBILITY COMPLEX PRODUCTS IN ANTIGEN-BINDING. EUR J IMMUNOL. 14:1101-1105.
LONDEI M; LAMB JR; BOTTAZZO GF; FELDMANN M. (1984). EPITHELIAL-CELLS EXPRESSING ABERRANT MHC CLASS-II DETERMINANTS CAN PRESENT ANTIGEN TO CLONED HUMAN T-CELLS. NATURE. 312:639-641.
LAMB JR; FELDMANN M. (1984). ESSENTIAL REQUIREMENT FOR MAJOR HISTOCOMPATIBILITY COMPLEX RECOGNITION IN T-CELL TOLERANCE INDUCTION. NATURE. 308:72-74.
ERB P; RAMILA G; STUDER S; LOEFFLER H; CECKA JM; CONSCIENCE JF; FELDMANN M. (1984). HETEROGENEITY OF ACCESSORY CELLS. IMMUNOBIOLOGY. 168:141-153.
LAMB JR; ZANDERS ED; LAKE P; WEBSTER RG; ECKELS DD; WOODY JN; GREEN N; LERNER RA; et alFELDMANN M. (1984). INHIBITION OF T-CELL PROLIFERATION BY ANTIBODIES TO SYNTHETIC PEPTIDES. EUR J IMMUNOL. 14:153-157.
TODD I; PUJOLBORRELL R; HAMMOND L; BOTTAZZO GF; FELDMANN M. (1984). INTERFERON-ALPHA INDUCES HLA-DR EXPRESSION BY THYROID EPITHELIUM. ANN ENDOCRINOL-PARIS. 45:39-39.
FELDMANN M. (1984). MECHANISM OF ACTION OF IMMUNE-RESPONSE GENES. ANN INST PASTEUR IMM. C135:402-407.
TODD I; PUJOLBORRELL R; HAMMOND L; BOTTAZZO GF; FELDMANN M. (1984). THE POTENTIAL FOR ANTIGEN PRESENTATION BY ENDOCRINE EPITHELIUM. IMMUNOBIOLOGY. 167:122-122.
JAMES RFL; KONTIAINEN S; MAUDSLEY DJ; CULBERT EJ; FELDMANN M. (1983). A MONOCLONAL-ANTIBODY AGAINST ANTIGEN-SPECIFIC HELPER FACTOR AUGMENTS T-CELL HELP. NATURE. 301:160-163.
ZANDERS ED; FISCHER A; SMITH S; BEVERLEY PCL; FELDMANN M. (1983). ANTIGEN-SPECIFIC AND NON-SPECIFIC HELPER ACTIVITIES DERIVED FROM SUPERNATANTS OF HUMAN INFLUENZA VIRUS-SPECIFIC T-CELL LINES. IMMUNOLOGY. 48:361-366.
LAMB JR; SKIDMORE BJ; GREEN N; CHILLER JM; FELDMANN M. (1983). INDUCTION OF TOLERANCE IN INFLUENZA VIRUS-IMMUNE LYMPHOCYTE-T CLONES WITH SYNTHETIC PEPTIDES OF INFLUENZA HEMAGGLUTININ. J EXP MED. 157:1434-1447.
BOTTAZZO GF; PUJOLBORRELL R; HANAFUSA T; FELDMANN M. (1983). ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY. LANCET. 2:1115-1119.
LAMB JR; ZANDERS ED; FELDMANN M; LAKE P; ECKELS DD; WOODY JN; BEVERLEY PCL. (1983). THE DISSOCIATION OF INTERLEUKIN-2 PRODUCTION AND ANTIGEN-SPECIFIC HELPER ACTIVITY BY CLONAL ANALYSIS. IMMUNOLOGY. 50:397-405.
ZANDERS ED; LAMB JR; FELDMANN M; GREEN N; BEVERLEY PCL. (1983). TOLERANCE OF T-CELL CLONES IS ASSOCIATED WITH MEMBRANE ANTIGEN CHANGES. NATURE. 303:625-627.
KATZ DR; CZITROM AA; FELDMANN M; OFLYNN K; SUNSHINE GH. (1982). A COMPARATIVE-STUDY OF ACCESSORY CELLS DERIVED FROM THE PERITONEUM AND FROM SOLID TISSUES. ADV EXP MED BIOL. 149:421-428.
FISCHER A; NASH S; BEVERLEY PCL; FELDMANN M. (1982). AN INFLUENZA-VIRUS MATRIX PROTEIN-SPECIFIC HUMAN T-CELL LINE WITH HELPER ACTIVITY FOR INVITRO ANTI-HEMAGGLUTININ ANTIBODY-PRODUCTION. EUR J IMMUNOL. 12:844-849.
KATZ DR; CZITROM AA; FELDMANN M; SUNSHINE GH. (1982). IA AND MACROPHAGES IN ALLOPROLIFERATION AND ALLOCYTOTOXICITY. ADV EXP MED BIOL. 155:601-609.
KONTIAINEN S; TODD I; FELDMANN M. (1982). SPECIFIC SUPPRESSION OF ANTIBODY-RESPONSES INVIVO .1. EFFECTS OF INVITRO PRODUCED SUPPRESSOR FACTOR. IMMUNOLOGY. 45:459-465.
KATZ DR; SUNSHINE GH; FELDMANN M. (1981). ANTIGEN PRESENTATION TO T-CELLS INVITRO. J PATHOL. 134:295-295.
REES A; FELDMANN M; WOODY JN; ERB P. (1981). GENETICS OF HUMAN T CELL-MONOCYTE INTERACTION IN HELPER-CELL INDUCTION. CLIN EXP IMMUNOL. 44:445-452.
FISCHER A; BEVERLEY PCL; FELDMANN M. (1981). LONG-TERM HUMAN T-HELPER LINES PRODUCING SPECIFIC HELPER FACTOR REACTIVE TO INFLUENZA-VIRUS. NATURE. 294:166-168.
KONTIAINEN S; CULBERT EJ; CECKA M; SIMPSON E; MCKENZIE IFC; FELDMANN M. (1981). T-CELL HYBRIDOMAS PRODUCING HAPTEN-SPECIFIC SUPPRESSOR FACTORS. IMMUNOLOGY. 43:747-754.
SUNSHINE GH; KATZ DR; FELDMANN M. (1980). DENDRITIC CELLS INDUCE T-CELL PROLIFERATION TO SYNTHETIC ANTIGENS UNDER IR GENE-CONTROL. J EXP MED. 152:1817-1822.
ERB P; VOGT P; MATSUNAGA T; ROSENTHAL A; FELDMANN M. (1980). NATURE OF T-CELL-MACROPHAGE INTERACTION IN HELPER-CELL INDUCTION INVITRO .3. RESPONSIVENESS OF T-CELLS DIFFERENTIATING IN IRRADIATION OR ALLOPHENIC CHIMERAS DEPENDS ON THE GENOTYPE OF THE HOST. J IMMUNOL. 124:2656-2664.
KANTOR F; FELDMANN M. (1979). INDUCTION OF HUMAN ANTIGEN-SPECIFIC AND NONSPECIFIC HELPER FACTORS INVITRO. CLIN EXP IMMUNOL. 36:71-77.
ERB P; MEIER B; MATSUNAGA T; FELDMANN M. (1979). NATURE OF T-CELL MACROPHAGE INTERACTION IN HELPER-CELL INDUCTION INVITRO .2. 2 STAGES OF T-HELPER-CELL DIFFERENTIATION ANALYZED IN IRRADIATION AND ALLOPHENIC CHIMERAS. J EXP MED. 149:686-701.
ERB P; GASSER M; STRASSER S; KONTIAINEN S; FELDMANN M. (1978). CELLULAR BASIS OF HUMORAL IMMUNE-RESPONSE IN MOUSE AND HAMSTER. FED PROC. 37:2032-2034.
BALTZ M; MAURER PH; MERRYMAN CF; FELDMANN M. (1978). COMPLEMENTATION OF H-2-LINKED IR GENES - USE OF HELPER FACTOR TO ANALYZE RESPONSES TO GLYPHE. IMMUNOGENETICS. 6:471-481.
HOWIE S; FELDMANN M. (1978). IMMUNE-RESPONSE (IR) GENES EXPRESSED AT MACROPHAGE-B LYMPHOCYTE INTERACTIONS. NATURE. 273:664-666.
ERB P; MEIER B; KRAUS D; VONBOEHMER H; FELDMANN M. (1978). NATURE OF T-CELL-MACROPHAGE INTERACTION IN HELPER CELL INDUCTION INVITRO .1. EVIDENCE FOR GENETIC RESTRICTION OF T-CELL-MACROPHAGE INTERACTIONS PRIOR TO T-CELL PRIMING. EUR J IMMUNOL. 8:786-792.
KONTIAINEN S; FELDMANN M. (1978). SUPPRESSOR-CELL INDUCTION INVITRO .4. TARGET OF ANTIGEN-SPECIFIC SUPPRESSOR FACTOR AND ITS GENETIC RELATIONSHIPS. J EXP MED. 147:110-122.
KONTIAINEN S; SIMPSON E; BOHRER E; BEVERLEY PCL; HERZENBERG LA; FITZPATRICK WC; VOGT P; TORANO A; et alMCKENZIE IFC; FELDMANN M. (1978). T-CELL LINES PRODUCING ANTIGEN-SPECIFIC SUPPRESSOR FACTOR. NATURE. 274:477-480.
KONTIAINEN S; FELDMANN M. (1977). CHARACTERISTICS OF INVITRO-INDUCED ANTIGEN-SPECIFIC SUPPRESSOR CELLS. SCAND J IMMUNOL. 6:718-718.
HOWIE S; FELDMANN M; MOZES E; MAURER PH. (1977). INVITRO STUDIES ON H-2 LINKED UNRESPONSIVENESS .1. NORMAL HELPER CELLS TO (T,G)-A-L AND GAT IN LOW AND NON-RESPONDER MICE. IMMUNOLOGY. 32:291-299.
HOWIE S; FELDMANN M. (1977). INVITRO STUDIES ON H-2-LINKED UNRESPONSIVENESS TO SYNTHETIC POLYPEPTIDES .3. PRODUCTION OF AN ANTIGEN-SPECIFIC T HELPER CELL FACTOR TO (T,G)-A-L. EUR J IMMUNOL. 7:417-421.
FELDMANN M; ERB P. (1977). REQUIREMENT FOR INTERACTIONS BETWEEN 2 SUBPOPULATIONS OF T-CELLS FOR HELPER CELL INDUCTION INVITRO. Z IMMUNITATSFORSCH. 153:217-225.
KONTIAINEN S; FELDMANN M. (1977). SUPPRESSOR CELL INDUCTION INVITRO .3. ANTIGEN-SPECIFIC SUPPRESSION BY SUPERNATANTS OF SUPPRESSOR CELLS. EUR J IMMUNOL. 7:310-314.
ERB P; MEIER B; FELDMANN M. (1976). 2-GENE CONTROL OF T-HELPER CELL INDUCTION. NATURE. 263:601-604.
KONTIAINEN S; FELDMANN M; BEVERLEY P. (1976). CHARACTERISTICS OF INVITRO-INDUCED SPECIFIC T SUPPRESSOR CELLS. SCAND J IMMUNOL. 5:447-448.
FELDMANN M; BEVERLEY P; ERB P; HOWIE S; KONTIAINEN S; MAOZ A; MATHIES M; MCKENZIE I; et alWOODY J. (1976). CURRENT CONCEPTS OF ANTIBODY-RESPONSE - HETEROGENEITY OF LYMPHOID-CELLS, INTERACTIONS, AND FACTORS. COLD SPRING HARB SYM. 41:113-118.
MAOZ A; FELDMANN M; KONTIAINEN S. (1976). ENRICHMENT OF ANTIGEN-SPECIFIC HELPER AND SUPPRESSOR T-CELLS. NATURE. 260:324-327.
KONTIAINEN S; FELDMANN M. (1976). SUPPRESSOR CELL INDUCTION INVITRO .1. KINETICS OF INDUCTION OF ANTIGEN-SPECIFIC SUPPRESSOR CELLS. EUR J IMMUNOL. 6:296-301.
FELDMANN M; KONTIAINEN S. (1976). SUPPRESSOR CELL INDUCTION INVITRO .2. CELLULAR REQUIREMENTS OF SUPPRESSOR CELL INDUCTION. EUR J IMMUNOL. 6:302-305.
GORCZYNSKI RM; FELDMANN M. (1975). B-CELL HETEROGENEITY - DIFFERENCE IN SIZE OF B-LYMPHOCYTES RESPONDING TO T-DEPENDENT AND T-INDEPENDENT ANTIGENS. CELL IMMUNOL. 18:88-97.
KONTIAINEN S; FELDMANN M. (1975). CONDITIONS FOR INDUCING T HELPER CELLS INVITRO. SCAND J IMMUNOL. 4:121-128.
FELDMANN M; HOWARD JG; DESAYMARD C. (1975). ROLE OF ANTIGEN STRUCTURE IN DISCRIMINATION BETWEEN TOLERANCE AND IMMUNITY BY B-CELLS. TRANSPLANT REV. 23:78-97.
ERB P; FELDMANN M. (1975). ROLE OF MACROPHAGES IN GENERATION OF T-HELPER CELLS .3. INFLUENCE OF MACROPHAGE-DERIVED FACTORS IN HELPER CELL INDUCTION. EUR J IMMUNOL. 5:759-766.
ERB P; FELDMANN M. (1975). ROLE OF MACROPHAGES IN INVITRO INDUCTION OF T-HELPER CELLS. NATURE. 254:352-354.
FELDMANN M; KONTIAINEN S; GREAVES MF; HOGG N; BOYLSTON A. (1975). ROLE OF T-CELL IMMUNOGLOBULIN IN CELL COOPERATION, T-CELL SUPPRESSION, AND ANTIGENIC-COMPETITION. ANN NY ACAD SCI. 249:424-437.
FELDMANN M; KILBURN DG; LEVY J. (1975). T-T INTERACTION IN GENERATION OF HELPER CELLS INVITRO. NATURE. 256:741-743.
FELDMANN M; GREAVES MF; PARKER DC; RITTENBE.MB. (1974). DIRECT TRIGGERING OF B-LYMPHOCYTES BY INSOLUBILIZED ANTIGEN. EUR J IMMUNOL. 4:591-597.
FELDMANN M; SCHRADER JW. (1974). MECHANISM OF ANTIGENIC-COMPETITION .2. INDUCTION BY SPECIFIC T-CELL PRODUCTS. CELL IMMUNOL. 14:255-269.
HUCHET R; FELDMANN M. (1974). TOLERANCE INDUCTION TO A HAPTEN PROTEIN CONJUGATE INVIVO - ARE SUPPRESSOR T-CELLS INVOLVED. EUR J IMMUNOL. 4:768-771.
KONTIANE.S; FELDMANN M. (1973). INDUCTION OF SPECIFIC HELPER CELLS IN-VITRO. NATURE-NEW BIOL. 245:285-286.
SCHRADER JW; FELDMANN M. (1973). MECHANISM OF ANTIGENIC-COMPETITION .1. MACROPHAGE AS A SITE OF A REVERSIBLE BLOCK OF T-B-LYMPHOCYTE COLLABORATION. EUR J IMMUNOL. 3:711-717.
WILSON JD; FELDMANN M. (1973). RELATIVE AFFINITY AND AVIDITY OF ANTIGEN-BINDING RECEPTORS OF T AND B ROSETTE-FORMING CELLS. NATURE-NEW BIOL. 245:177-180.
TIGELAAR RE; FELDMANN M. (1973). SYNERGY AMONG THYMOCYTES AND PERIPHERAL LYMPH-NODE CELLS IN IN-VITRO GENERATION OF LYMPHOCYTES CYTOTOXIC TO ALLOANTIGENS. TRANSPL P. 5:1711-1715.

Chapters in books

Feldmann M; Brennan FM; WIlliams RO; Woody JN; Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. In Scientific Basis of Rheumatology: Best Practice & Research, Clinical Rheumatology. 18 (1):59-80. Klareskog L (ed); Lindblad S (ed). Bailliere Tindall (2004).
Andreakos E; Feldmann M. Autoimmunity and cytokines: pathogenesis and therapy. In Cytokine Handbook, 4th Edition. 1189-1211. Thomson AW (ed); Lotze MT (ed). Academic Press (2003).
Feldmann M; Brennan FM; Williams RO; Maini RN. Definition of TNFalpha as a therapeutic target for rheumatoid arthritis. In TNFalpha inhibition in the treatment of rheumatoid arthritis. 1-22. Moreland LW (ed); Emery P (ed). Martin Dunitz, London (2003).
Maini RN; Feldmann M. Infliximab therapy. In TNFalpha inhibition in the treatment of rheumatoid arthritis. 23-45. Moreland LW (ed); Emery P (ed). Martin Dunitz, London (2003).
Feldmann M; Maini RN.. TNFalpha. In Targeted Therapies in Rheumatology. 201-212. Smolen J (ed); Lipsky P (ed). Martin Dunitz Ltd., London (2003).
Bondeson J; Feldmann M; Maini RN. Gene therapy approaches for rheumatoid arthritis. In Gene Therapy: the use of DNA as a drug. 215-265. (2002).
Feldmann M; Maini RN. Anti-TNFalpha therapy in rheumatoid arthritis and other diseases. In Samter's Immunologic Diseases (Sixth Edition). 1180-1198. Austen KF (ed); Frank MM (ed); Atkinson JP (ed); Cantor H (ed). Lippincott Williams & Wilkins (2001).
Feldmann M; Brennan FM. Cytokines and disease. 35-51. (2001).
Oppenheim JJ; Feldmann M. Introduction to the role of cytokines in innate host defense and adaptive immunity. 3-20. (2001).
Feldmann M; Saklatvala J. Proinflammatory cytokines. 291-305. (2001).
Feldmann M; Brennan FM; Foxwell BMJ; Maini RN. The role of TNF? and IL-1 in rheumatoid arthritis. 188-199. (2001).
Aggarwal BB; Samanta A; Feldmann M. TNF receptors. 1619-1632. (2001).
Aggarwal BB; Samanta A; Feldmann M. TNF?. 413-434. (2001).

Conferences

Feldmann M. The TNF/TNF-R Family: A Gold Mine for Clinical Therapeutic Targets? Introduction. 691:IX-X. (2011).
Krausgruber T; Blazek K; Smallie T; Lockstone H; Sahgal N; Alzabin S; Hussell T; Feldmann M; et alUdalova I. IRF5 PROMOTES INFLAMMATORY MACROPHAGE POLARIZATION AND TH1/TH17 RESPONSE. 50:54-54. (Apr 2011).
Kong PL; Timms E; Coulson A; Blagoeva K; Potter P; Feldmann M. Discovering novel regulatory pathways of imflammation by ENU mutagenesis. 131:106-106. (Dec 2010).
Gregan SM; Navin TJ; Georgiou E; Foxwell BM; Davies AH; Feldmann M; Monaco C. Toll-like Receptor-2 and-4 Signaling Regulates Inflammation and Matrix Degradation in the Human Atherosclerotic Plaque. 120:S1138-S1138. (3 Nov 2009).
Monaco C; Gregan SM; Navin TJ; Foxwell BMJ; Davies AH; Feldmann M. TOLL-LIKE RECEPTOR-2 MEDIATES INFLAMMATION AND MATRIX DEGRADATION IN HUMAN ATHEROSCLEROSIS. 95. (15 Nov 2009). DOI.
Fertleman M; Mani S; Nurse B; Hobson J; Nanchahal J; Vizcaychipi M; Harrison J; Ritchie CW; et alFeldmann M; Maze M. Effective cognitive assessment in the management of post-operative delirium. 16:199-199. (Oct 2009).
Feldmann M. Anti TNF and the beginning of anti cytokine medicine. 43:231-231. (Sep 2008). DOI.
Kuai J; Gregory B; Hill A; Pittman DD; Feldman JL; Brown T; Carito B; OToole M; et alRamsey R; Shields KM; Beech JT; Nanchahal J; Feldmann M; Foxwell BM; Brennan FM. TREM-1 expression is increased in the Synovium of Rheumatoid Arthritis patients and induces the expression of pro-inflammatory cytokines. 43:254-255. (Sep 2008). DOI.
Larsen H; Feldmann M; Paleolog E. Synovial fibroblasts are important mediators of synovial angiogenesis in the hypoxic rheumatoid joint. 27th European Workshop for Rheumatology Research. 66:A61-A61. (1 Mar 2007).
Persson L; Navin T; Gregan S; Davies AH; Feldmann M; Monaco C. TF ligation by factor VIIa induces pro-inflammatory cytokine production in atheroma smooth muscle cells. World Congress of Cardiology. 27:455-455. (Aug 2006).
Persson L; Navin T; Gregan S; Davies AH; Feldmann M; Monaco C. Inhibition of tissue factor signalling reduces production of pro-inflammatory cytokines in atheroma smooth muscle cells. 7:92-93. (Jun 2006).
Edwards L; Snelgrove R; Feldmann M; Hussell T. Modification of collagen-induced arthritis by education or manipulation of antigen presenting cells. 45:I18-I18. (Apr 2006).
Danks L; Owen S; Feldmann M; Brennan F; Horwood NJ. NK cells support osteoclast formation in vitro. 44:I30-I30. (Mar 2005).
Inglis JJ; Anand P; Facer P; Criado G; Feldmann M; Williams RO. Exploring mechanisms of inflammatory hyperalgesia in murine collagen-induced arthritis. 7:S44-S45. (Feb 2005). DOI.
Criado G; Inglis JJ; Feldmann M; Williams RO. Treatment of collagen-induced arthritis with cholera toxin-treated dendritic cells. 7:S51-S51. (Feb 2005). DOI.
Bondeson J; Evans A; Lauder S; Amos N; Feldmann M. Adenoviral gene transfer into cells from diseased tissue as a tool to investigate the regulation of inflammatory and destructive mediators in the osteoarthritis synovium. 63:64-64. (Jul 2004).
Maini RN; Feldmann M. The introduction of TNF blockade in rheumatoid arthritis. Annual European Congress of Rheumatology (EULAR 2004). 63:13-13. (Jul 2004).
Feldmann M; Maini RN. The role of TNF ininflammatory joint disease. Annual European Congress of Rheumatology (EULAR 2004). 63:12-13. (Jul 2004).
Pertynska-Marczewska M; Kiriakidis S; Foxwell B; Feldmann M; Paleolog EM. Advanced glycation end products (AGEs) augment production of vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF alpha) in human monocyte-derived macrophages. 46:A407-A407. (Aug 2003).
Monaco C; Paleolog E; Cheshire N; Feldmann M. Direct analysis of gene expression and regulation in human atherosclerotic tissue: Nuclear factor kappa B regulates production of cytokines and tissue factor. American-Heart-Association Abstracts From Scientific Sessions. 106:259-259. (5 Nov 2002).
Zhang YH; Levin J; Xu J; Hegen M; Keith J; Li GD; Robertshaw H; Brennan F; et alFeldmann M; Nickerson-Nutter C; Kohlbrenner M; Gibbons J; Larsen G; Lin LL. Development of a novel dual TACE/MMP inhibitor for treatment of RA. 46:S136-S136. (Sep 2002).
Monaco C; Andreakos E; Kinakidis S; Feldmann M; Paleolog E. Inhibition of tissue factor by blockade of NFkB and IKK-2 using gene transfer: NFkB as a therapeutic target for reducing plaque thrombogenicity. Congress of the European-Society-of-Cardiology. 23:20-20. (Aug 2002).
Monaco C; Paleolog E; Cheshire N; Feldmann M. NFkB and IkB kinase-2 regulate tissue factor and cytokine production in human atherosclerotic plaques: an analysis via adenoviral gene transfer. Congress of the European-Society-of-Cardiology. 23:261-261. (Aug 2002).
Kiriakidis S; Monaco C; Andreakos E; Foxwell B; Feldmann M; Paleolog E. VEGF expression in human macrophages is NFkB-dependent: studies using adenoviral gene transfer. Congress of the European-Society-of-Cardiology. 23:382-382. (Aug 2002).
FELDMANN M; BRENNAN FM; CHU CQ; COPE AP; GIBBONS D; MAINI RN. DOES TNF-ALPHA HAVE A PIVOTAL ROLE IN THE CYTOKINE NETWORK IN RHEUMATOID-ARTHRITIS. 144-152. (1993).
FELDMANN M; DAYAN C; RAPOPORT B; LONDEI M. T-CELL ACTIVATION AND ANTIGEN PRESENTATION IN HUMAN THYROID AUTOIMMUNITY. 5:115-121. (Apr 1992).
MAINI RN; PLATERZYBERK C; BROWN CMS; AGHAMOHAMMADI S; BRENNAN FM; FELDMANN M. CD5+B CELLS IN RHEUMATOID-ARTHRITIS AND SJOGRENS-SYNDROME. 8:67-68. (Jul 1990).
TURNER M; CHANTRY D; LANE A; FELDMANN M. MODULATION OF CYTOKINE PRODUCTION AND FUNCTION BY TRANSFORMING GROWTH-FACTOR-BETA. 2ND INTERNATIONAL WORKSHOP ON CYTOKINES. 10:477-482. (1990).
DAYAN CM; LONDEI M; CORCORAN AE; RAPOPORT B; FELDMANN M. SPECIFIC RECOGNITION OF THYROID PEROXIDASE BY THYROID INFILTRATING T-CELL CLONES IN HUMAN AUTOIMMUNE-THYROIDITIS. 207:267-267. (1990).
CHANTRY D; BRENNAN F; TURNER M; VARMA C; KATZ F; FELDMANN M. STIMULATION OF HUMAN AND MURINE THYMOCYTE PROLIFERATION BY INTERLEUKIN-7. 10:535-540. (1990).

Patents

Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease. Patent number: US No: 6/270,76B1. Maini RN. Published: 7 Aug 2001.
Method for treating multiple sclerosis. Patent number: US 5,741,488. Turk JL; Baker D. Published: 4 Feb 2000.
TNF Receptor Variant (Modified Human TNF Receptor). Patent number: USA 863,786. Published: 26 Jan 1999.
Treatment of Rheumatoid Arthritis with Anti-CD4 Antibodies in Conjuction anti-TNF Antibodies. Patent number: US Patent 5,741,488. Maini RN; Williams R. Published: 21 Apr 1998.
Treatment of Auto-Immune and Inflammatory Disorders. Patent number: European patent 0 663 836. Published: 9 Jul 1997.
TNF Receptor Variant (Modified Human TNF Receptor). Patent number: USA 5,633,145. Published: 27 May 1997.
Activation and inhibition of the immune system. Foxwell B.
Adenoviral vectors. Patent number: WO01/21823 (PCT - International Patent Application). Foxwell B. Filed: 29 Mar 2001.
Composition, kits and methods for indentification and modulation of T helper-1 and T-helper-2 cells and diseases associated therewith. Patent number: USSN 60/205,204.
Immunostimulating molecule.
Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with TNF antagonists. Patent number: PCT/GB97/00435 & Japan 97 90 3485.7. Elliott M; Maini RN.
Methods of preventing or treating thrombosis with tumor necrosis factor antagonists. Application: US Appl'n 08/602,272. Elliott MJ; Maini RN.
Modified human TNF receptor. Patent number: US 5,633,145 & 5,863,786 & Eur 0556207. Gray P; Turner M; Brennan F.
Multiple administrations of anti-TNF antibody. Patent number: US Appl'n 08/446,674. Maini RN; Woody J.
Oncogene transformed cell lines. James R; Gray P; Foxwell B.
Polymorphism Assay. Application: Appl'n PCT/GB 00/03642.
Reporter genes (in adenovirus). Foxwell B.
Small molecular weight TNF receptor multimeric molecule. Application: US Appl'n 09/285,531. Chernajovsky Y; Neve R.
Suppresion of TNF alpha and IL-12 in therapy. Malfait A; Butler D; Brennan F; Maini RN.
Suppression of TNFalpha and IL-12 therapy. Application: US Appl'n 08/749,979. Malfait A; Butler D; Brennan F; Maini RN.
Suppression of TNFalpha and vascular endothelial growth factor in therapy. Application: US Appl'n 08/854,881. Maini RN; Paleolog E.
Therapeutic methods & compounds. Application: Appl'n No PCT/GB 00/03660. Foxwell B; Brennan F.
Therapeutic Methods & Compounds. Application: WO 01/21202. Brennan F; Foxwell B. Filed: 29 Mar 2001.
TNF promoter & reporter genes. Application: PCT/GB Appl'n No 00/03645.
TNFalpha antagonists and cyclosporin in the therapy of rheumatoid arthritis. Application: US Appl'n 09/093,450.
Use of cannabinoids as anti-inflammatory Agents. Patent number: PCT/GB 99/01140. Malfait A; Gallily R; Mechoulam R.
Use of cannabinoids as anti-inflammatory agents. Filed: 31 Jan 2001.
Viral Infection of Cells. Patent number: Appln No PCT/GB 98/02753 & Eur 98942892.5. Foxwell B; Brennan F; Bondeson J.

Publications

Journals

Chapters in books

Conferences

Patents

Email to a Friend

Page URL:

Your Information:

Friend's Information: